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ABSTRACT
Ribosomally Synthesized and Post-Translationally Modified Peptides as
Potential Scaffolds for Peptide Engineering
Devan Bursey
Department of Microbiology and Molecular Biology, BYU
Master of Science
Peptides are small proteins that are crucial in many biological pathways such as
antimicrobial defense, hormone signaling, and virulence. They often exhibit tight specificity for
their targets and therefore have great therapeutic potential. Many peptide-based therapeutics are
currently available, and the demand for this type of drug is expected to continue to increase. In
order to satisfy the growing demand for peptide-based therapeutics, new engineering approaches
to generate novel peptides should be developed. Ribosomally synthesized and posttranslationally modified peptides (RiPPs) are a group of peptides that have the potential to be
effective scaffolds for in vivo peptide engineering projects. These natural RiPP peptides are
enzymatically endowed with post-translational modifications (PTMs) that result in increased
stability and greater target specificity. Many RiPPs, such as microcin J25 and micrococcin, can
tolerate considerable amino acid sequence randomization while still being capable of receiving
unique post-translational modifications. This thesis describes how we successfully engineered E.
coli to produce the lasso peptide microcin J25 using a two-plasmid inducible expression system.
In addition, we characterized the protein-protein interactions between PTM enzymes in the
synthesis of micrococcin. The first step in micrococcin synthesis is the alteration of cysteines to
thiazoles on the precursor peptide TclE. This step is accomplished by three proteins: TclI, TclJ,
and TclN. We found that a 4-membered protein complex is formed consisting of TclI, TclJ,
TclN, and TclE. Furthermore, the TclI protein functions as a central adaptor joining two other
enzymes in the Tcl pathway with the substrate peptide.

Keywords: peptide engineering, post-translational modifications, thiazole, lasso peptides,
thiopeptides
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CHAPTER 1: Introduction
1.1 The power of peptides as potential therapeutic molecules
Peptides are short chains of amino acids that are ubiquitous in nature and are of great
interest in the pharmaceutical industry. Peptides are crucial in a wide array of biological
pathways and therefore possess a myriad of functions, including hormone signalling,
antimicrobial activity, virulence, and cell-cell communication (2, 3). Since peptides are involved
in many natural pathways across various species, they may easily be adapted into therapeutics in
a way that closely mimics nature (3, 4). In addition to having vast target potential, peptides make
excellent drug candidates because they typically are highly effective and discriminatory at
binding to specific proteins. For example, some natural peptides can bind to various G proteincoupled receptors (GPCRs) and the elongation factor EF-Tu (3-5). Thus, peptides are innately
primed with low off-target effects in hosts. Peptides are composed of amino acids, which are
abundant in all living organisms, allowing them to also have low-immunogenicity to human
hosts (6). This optimal pharmacological profile grants them a unique niche in between small
molecules and larger biological entities like monoclonal antibodies (2, 3, 6, 7).
Global peptide-based therapeutic market
Peptide based therapeutics are found across various fields such as oncology, metabolic
diseases, cardiovascular health, and infectious diseases (6). Currently there are over 60 peptide
drugs approved for use in the United States (Table 1) and over 500 more peptide-based drugs
currently in clinically trials (4, 8). In 2017, peptide-based therapeutics sales brought in more than
$20 billion US dollars alone (3, 8). Some approved peptide-based pharmaceuticals such as
calcitonin and ecallantide are described in Table 1. Many of these peptide-based drugs such as
liraglutide (trademarked Victoza) are based on naturally occurring peptides (3). Victoza is an
analog to a naturally occurring peptide called glucagon-like peptide-1 (GLP-1) (3). In humans
1

GLP-1 binds to the GLP-1 receptor triggering a biological cascade that enhances the secretion of
insulin. Victoza also stimulates increased insulin expression and is available for treatment of
treatment type 2 diabetes mellitus (3).
Table 1. Approved Therapeutic Peptides
Peptide

Mode of action

Therapeutic use

Calcitonin (4, 6)

Calcitonin is a hormone that
increases calcium retention

Treatment for bone
diseases such as
osteoporosis and to
reduce high blood
pressure

1971

Bivalirudin (6)

It inhibits both circulating
and clot-bound thrombin

Thins the blood to
prevent blood clots

2000

Daptomycin (6)

Disrupts the bacterial cell
membrane

Treatment of grampositive bacterial
infections

2003

Enfuvirtide (6)

HIV fusion inhibitor

Treatment of HIV

2003

Ecallantide (9)

Inhibits kallikrein

Treatment for
hereditary
angioedema

2009

Victoza (6)

Derivative of human
incretin, glucagon-like
peptide 1 (GLP) and
stimulates insulin secretion

Treatment of type 2
diabetes

2010

Afamelanotide (6)

Synthetic peptide analogue
of α-melanocyte stimulating
hormone and drives
melanogenesis

Treatment to
prevent skin
damage from sun in
people with
erythropoietic
protoporphyria

2015

Tymlos (8)

Selective activation of
parathyroid hormone 1
receptor

Treatment for
osteoporosis

2017

2

Year of
Approval

Giapreza (8)

Acts on the CNS to increase
ADH production

Control of blood
pressure in adults in
critical condition

2017

Macrilen (8)

Mimics the endogenous
ligand for Ghrelin

Diagnosis of adult
growth hormone
deficiency

2017

Trulance (8)

Mimics uroguanylin and
guanylin and increases
intestinal fluids

Used to treat
irritable bowel
syndrome with
constipation

2017

1.2 Engineering peptides with designer modifications
Despite the success of peptide therapeutics, there are several limitations of native
peptides that have tempered their development into drugs. Peptides have low bioavailability
because they are easily degraded by digestive enzymes. Thus, most peptide drugs are
administered parenterally, a method of drug delivery less attractive to patients (4, 6). Once inside
the body, peptides have a short half-life because they are cleaved by cellular peptidases and are
easily excreted through the kidneys (4, 6). Peptides are also often hydrophobic which can make
crossing the cell membrane and reaching their molecular targets difficult (2, 6). Therefore,
scientists have been developing tactics to overcome these apparent handicaps. Many of these
solutions consist of particular chemical features such as the incorporation of unnatural amino
acids to create D-peptides and stapled peptides (4, 7, 10).

3

Fig. 1. Examples of ways to engineer peptides with
unnatural amino acids. A, depiction of L-alanine compared
to D-alanine. B, simple representation of how a stapled
peptide is made. Two unnatural amino acid with a
hydrocarbon chain are incorporated into the peptide.
Those two hydrocarbons react to form a heterocyle. The
brackets on the peptide chain represent that the bracket
region can be expanded to show more residues that are
inbetween the two unnatural amino acids.

D- vs L- amino acid incorporation
There are two isoforms for each amino acid (excluding glycine) which are designated as
either a D- (right) amino acid or L- (left) amino acid (Fig. 1A.) In nature, biology uses almost
exclusively L-amino acids, with a notable exception of the incorporation of D-amino acids into
the peptidoglycan of bacterial cell walls (11, 12). Therefore, naturally occurring peptides are also
composed of L-amino acids which makes them intrinsically susceptible to proteolysis by the
many proteases present in vivo thereby decreasing their biostability (11, 12). For example,
P113D is an antimicrobial drug derived from histatin that has D-amino acids incorporated into it.
With the incorporation of D-amino acids P113D has increased stability and becomes biologically
active in the sputum of patients with cystic fibrosis unlike the natural L-amino acid version of
P113.
4

Stapled peptides
Another solution to rigidify the structure of a peptide is to create a stapled peptide (5)
(Fig. 1B). Linear peptides possess numerous rotatable bonds that allow them conformational
freedom to alternate different structures. This physical fluidity can weaken peptide stability (10,
13, 14). A stapled peptide is locked into a fixed conformational structure by hydrocarbon
crosslinks. This can be accomplished by incorporating distinct unnatural amino acids into
successive turns in the peptide (10, 13, 14). These amino acids have been modified to contain
special hydrocarbon side chains which interact with each other to form a ring structure,
effectively securing the α-helix structure of the peptide Fig. 1B (10, 13, 14). These unnatural
amino acids get incorporated into the peptide when the peptide is being chemically synthesized.
Then cyclization of the hydrocarbon side chains is initiated by adding various chemical catalysts.
One of the first examples of this method was done on an HIV-1 fusion inhibitor T649. When
staples were introduced into this peptide it was resistant to chymotrypsin cleavage and
demonstrated increased anti-viral activity (14).
Need for innovative peptide library design
Mining peptides from nature is advantageous because they have been evolutionarily
selected to bind to their specific target and maintain a certain level of stability; however, there is
a limit to the number of naturally occurring peptides (3, 6), and natural peptides are not typically
perfectly adapted to therapeutic needs. Since the global market for peptide therapeutics is
expected to almost double by 2025 reaching approximately $50 billion US dollars, it is
imperative that novel and innovative peptides be discovered and developed (3, 6, 8). One way of
discovering novel peptide drugs is by creating large peptide libraries. These novel peptide
libraries can be created chemically or in living cells such as bacteria.

5

Synthesizing peptides chemically versus in cells
The standard method for chemically synthesizing peptides is a process pioneered by Dr.
Robert Merrifield known as solid-phase synthesis (2, 6). Solid-phase synthesis is a step-wise
process for the C- to N- terminus construction of a polypeptide chain attached to a resin bead (2,
6). One of the advantages of chemically synthesizing peptide libraries is that it is possible to
incorporate designer features such as unnatural amino acids which can increase peptide stability
(e.g. D-amino acids and stapled peptides). In addition, chemically synthesized peptides can be
easily purified since the resin bead acts as a purification tag (2, 6). Some disadvantages to
chemically synthesized peptide libraries are low product yield, inability to synthesize large
peptides, and peptides are synthesized in individual reactions thus limiting library size. (2, 6, 15,
16).
An alternative method to creating peptides is to genetically engineer bacteria, this can be
accomplished by having the desired peptide sequence encoded on a plasmid in the cell and
having the ribosome synthesize the product (2). A great advantage to synthesizing peptides in
cells is the scalable product yield (6). Another ideal quality is that there is potential to create vast
peptide libraries simply by randomizing the amino acid sequence of the peptide encoded on a
plasmid. By randomizing five amino acids in a peptide, one can generate approximately 205 (3.2
million) novel peptides. Some major disadvantages to generating peptide libraries in living cells
is that overexpressing certain proteins can be toxic to cells, or some proteins may not express
well (17). One major drawback of synthesizing peptides produced by bacteria compared to
chemical synthesis is that historically bacterially produced peptides cannot be made to
incorporate special chemical modifications onto their side chains (2, 6). Therefore, developing
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methods to make post-translational modifications on peptides is important to enhance the
potential of bacteria to generate peptide libraries for therapeutic studies (18, 19).
Post-translational modification installation
There are many types of post-translational modifications (PTMs) that occur in a cell, such
as glycosylation, lysine acetylation, phosphorylation, ubiquitinylation, heterocycle formation,
dehydration, etc. (20, 21) (Fig. 2). These PTMs get incorporated onto peptides through the
activity of various enzymes. All PTM incorporating enzymes exhibit a certain affinity for their
substrates (22). However, from an engineering perspective, there is a trade-off between
substrate-specificity and substrate-permissiveness (23, 24). There are varying levels to which an
enzyme modulates its selectivity. An enzyme might recognize its substrate based on adjacent or
nearby sequence (regioselectivity), identity of the modified side chain (chemoselectivity), or
through remote sites on the substrate protein (alloselectivity) (Fig. 3). Some enzymes, such as

Fig. 2. Some post-translational modifications found in
nature. Chemical structures for several different post
translational modifications.
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Fig. 3. Depiction of three levels of selectivity
exhibited by PTM enzymes. See text for
details.

kinases, exhibit remarkable specificity for their substrate based on these three levels. Many
kinases require serine/threonine (or tyrosine) at the phosphorylation site (chemoselectivity),
preferring side chains in close proximity to residues of phosphorylation (regioselectivity) and
often binding with the substrate peptide on far-away regions from the enzyme active site
(alloselectivity) (25-27). Other enzymes are far looser in their level of specificity. For example,
the cyanobactin subtilisin-like serine protease PatG is an enzyme responsible for the
macrocyclization in the cyanobacterial patellamide pathway. It exhibits a fairly relaxed substrate
specificity so long as a short C-terminal sequence AYDE (E) is present (28, 29). This allows
PatG to act on 29 known natural variant patellamide-precursor peptides (29). Interestingly, PatG
can form macrocyles anywhere between 5 to 22 amino acids in size. In addition, a study was
carried out using synthetic peptides and PatG, which showed that PatG can act on peptides of
varying length and even those that contain unnatural amino acids and D-amino acids (30).
Substrate promiscuity does come at a cost, as PatG reactions tend to happen at a very slow rate
(30). Most widely tolerant PTM enzymes have a decreased kinetic rate (19). These loose PTM
8

enzymes with low regioselectivity are of great interest. They can be developed into a powerful
tool that would use a constant handle that is sufficient to recruit the PTM enzyme but allows for
adjacent peptide sequences to be modified in diverse sequence contexts (18, 19). By pairing a
promiscuous PTM enzyme with a variety of random peptides bearing the appropriate PTM
enzyme-recognition handle, it would be possible to generate a large post-translationally modified
peptide library in bacterial cells (18, 19, 31, 32). There is also the potential that one could pair
two promiscuous enzymes from different biosynthetic pathways together to generate even more
complex and structurally diverse peptide libraries (18, 19). An ideal platform would use enzymes
with minimized regioselectivity (i.e. many sequence contexts are tolerated) but maintain high
chemoselectivity and alloselectivity. An enticing natural template for this type of bioengineering
project are ribosomally synthesized and post-translationally modified peptide biosynthetic
pathways, such as thiopeptides and lasso peptides.
1.3 Natural post-translationally modified peptide pathways as potential library scaffolds
Introduction to ribosomally synthesized and post-translationally modified peptides
Ribsomally synthesized and post-translationally modified peptides (RiPPs) possess many
enzymatic chemical alterations which drastically alter their structures and functions. RiPPs are
produced by many different organisms and there are currently over 20 different classes of RiPPs
such as lanthipepides, cyanobactins, thiopeptides, proteucins, microviridins, bottromycins, lasso
peptides and linaridians (33, 34). Several of these families lend themselves to in vivo
randomization, therefore they have the potential to be used as scaffolds to generate thousands of
new potentially biologically active peptides (18, 19, 31, 32). While each RiPP family possesses
a unique structural arrangement with a distinctive profile of PTMs, RiPPs generally follow the
same biosynthetic logic (Fig. 4) (35). RiPPs are synthesized on the ribosome as linear precursor
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peptides which are then subsequently enzymatically modified to their final structure. The
precursor peptide is composed of two functional parts: the leader region and the core region. The
leader region is usually involved in initial recognition by modifying enzymes while the core
region receives the modifications and eventually becomes the active peptide product after leader
removal (Fig. 4) (33, 35). Since most PTM enzymes recognize the leader peptide, RiPP core
peptides can be mutated and the enzymes can still modify them provided the leader peptides
remains intact (18, 19). Lasso peptides and thiopeptides are the two families of RiPPs that will be
elaborated on further (31, 32).

Fig. 4. General biosynthetic pathway of RiPPs. RiPP maturation begins with the
production of a bipartite precursor peptide. This peptide consists of an N-terminal
leader and a C-terminal core. The core gets extensively modified by PTM enzymes
and the leader gets cleaved from the altered core to result in the mature RiPP.

Introduction to lasso peptides
Lasso peptides are a RiPP family that were first discovered in 1991 and are primarily
produced by Proteobacteria and Actinobacteria (36). There are currently 35 known lasso
peptides (36). Lasso peptides follow the same general maturation pathway as other RiPPs,
beginning as a bipartite precursor peptide that gets transformed into a mature peptide by enzymes
(32, 36, 37). These lasso peptides exhibit a wide array of functions, including antimicrobial
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activity, and are characterized by their unique, knot-like shape (Fig. 5) (32, 36, 37) . The Cterminal tail gets threaded through a 7-9 amino acid N-terminal ring, forming a loop (36, 38-40).
The loop topology is usually stabilized by steric interactions and their structure makes them
highly resistant to proteases. There is evidence in the literature that some lasso peptides, like
microcin J25, can be modified to produce thousands of unique peptides (1, 32, 37).

Fig. 5. Lasso peptide structure. A, a simple graphic to show the general
structure of lasso peptide. B, the structure of lasso peptide microcinJ25.

Introduction to thiopeptides
Thiopeptides are a large RiPP family that boasts over 100 members (Fig. 6) (41, 42).
They make attractive scaffolds for engineering novel peptides due to their wide variety of
biological properties (31). Many possess antimicrobial activity, specifically against Grampositive bacteria usually through inhibition of translation either by interfering with the elongation
factor EF-Tu or the 50S ribosomal subunit (41, 43). In addition, they have demonstrated antiviral, anti-parasitic, immunosuppressive, and anti-proliferative effects (41, 43). The hallmark of a
thiopeptide is a six-membered nitrogenous ring that closes a peptide macrocycle. Certain
thiopeptides such as thiostrepton A contain two macrocycles. In addition, thiopeptides also
11

Fig. 6. Four representative thiopeptide structures. Thiostrepton A and nosipeptide are bimacrocyclic
thiopeptide structures. Micrococcin and thiomuracin are both monomacrocylic thiopeptide structures.

contain azoles rings (thiazoles and oxazoles), dehydroamino acids, and other pathway-specific
alterations (41, 43, 44). Thiopeptides begin as linear precursor peptides 20-110 amino acids in
length which are then enzymatically endowed with chemical alterations. Canonically, the Cterminal core peptide is used as the substrate for all the subsequent PTMs. The N-terminal leader
region is usually involved in initial recognition by modifying enzymes, but eventually it is
cleaved and only the core remains in the final peptide architecture.
Microccocin, a model thiopeptide
We have been studying the archetypal thiopeptide micrococcin that is produced by gram
positive bacteria species like Macrococcus caseolyticus and Bacillus cereus (43) (Fig. 6.). In
recent years, a plasmid-based gene cluster for the production of micrococcin from Macrococcus
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Fig. 7. Micrococcin biosynthesis. A, Gene cluster for micrococcin synthesis. B,
biosynthetic pathway of micrococcin synthesis.

caseolyticus has been described (42, 45). The gene cluster for complete micrococcin synthesis in
the M. caseolyticus system has been identified, and consists of 12 protein-coding genes (8 of
which are required for micrococcin biosynthesis), making it a relatively simple model
thiopeptide biosynthetic pathway (Fig. 7A) (42). TclE is the precursor peptide which acts as the
substrate that gets manipulated by the PTM enzymes to eventually become the mature
13

thiopeptide. It follows typical RiPP precursor peptide composition possessing a 35 amino acid Nterminal leader and a 14 amino acid C-terminal core (Fig. 7B). The maturation of micrococcin
begins with the installation of six thiazoles from the six cysteines present in the core region. This
step is carried out by three proteins: TclI, TclJ, and TclN. Thiazole installation is followed by a
C-terminal decarboxylation step, carried out by TclP (46). Next, serine/threonine dehydration is
brought about by TclK and TclL on several serine and threonine residues within the core region.
Micrococcin maturation is culminated by a macrocyclization event initiated by TclM forming a
pyridine ring out of the two dehydrated serine side chains (Fig. 7). Of greatest interest to us for
the future development of creating in vivo systems capable of installing PTMs on peptide
libraries are those proteins involved heterocycle formation: TclJ, TclN, TclI, and TclE (42, 43,
45, 46).
1.4 Heterocycle formation using TOMM biosynthetic enzymes
Heterocycle installation
The formation of heterocycles such as thiazoles (derived from cysteines) or oxazoles
(derived from serine/threonine) in thiopeptides is a two-step process. This process begins with a
cyclodehydration event to form an azoline, followed by a dehydrogenation step to create the
more stable aromatic azole (Fig. 8) (47, 48). Heterocycle formation is not unique to thiopeptides
and is a pattern that appears in many other RiPP families such as cyanobactins and lanthipeptides
(49, 50). The process involves three different proteins: a heterocyclase, a precursor peptide
recognition protein and a dehydrogenase (Fig. 8). The heterocyclase, dehydrogenase, and
precursor peptide recognition protein are classified into a group called thiazole/oxazolemodified microcins (TOMM) biosynthetic enzymes (47). Typically, both the heterocyclase and
precursor peptide recognizing protein are involved in azoline formation. The heterocyclase is
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primarily responsible for catalysis of cyclodehydration. The heterocyclase consists of an ATPdependent YcaO domain with a proline rich C-terminus (PXPXP) which bestows upon it
azoline-incorporating capability (51-53). The protein involved in precursor peptide recognition
has one domain that usually contains some sort of N-terminal winged-helix-turn-helix structure
which is defined as the RiPP precursor peptide recognition element (RRE). This RRE allows the
protein to bind to the leader peptide (35, 54). This binding presumably helps to accurately guide
the core of the precursor peptide to the active site of the heterocyclase. In approximately half of
the known TOMM biosynthetic gene clusters the heterocyclase and precursor peptide
recognition protein are fused together (e.g. LynD of the aestuaramide pathway and TruD of the
trunkamide pathway) showcasing the importance of the involvement of both proteins in
cyclodehydration (30, 47, 52). The dehydrogenases are FMN-dependent and oxidize azolines to
azoles (Fig. 8). There is great sequence diversity amongst dehydrogenase proteins but they all
belong to the nitroreductase superfamily and appear to have a conserved Lys-Tyr motif near the
FMN binding site (55, 56). Dehydrogenases can function as a single protein or fused to another
protein (e.g. PatG involved in patellamide biosynthesis) (57, 58). In pathways where the terminal
heterocycle form is a thiazoline or oxazoline then a dehydrogenase may be absent (47, 48).
Processing requirements for TOMM enzymes
The enzymatic requirements for substrate processing, including complex formation,
direction of processing, chemo-, regio-, and allo-specificity vary amongst TOMM gene clusters.
Some other studied TOMM enzymatic pathways include microcin B17 (59-61), steptolysin S
(62, 63), hakacin (54, 64), patellamide A (57, 65, 66), and thiomuracin A (67, 68) (Fig. 9). The
order in which post-translational modifications are installed along the core varies from system to
system. For example, processing of the core can happen from the N- to C- terminus like in the
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Fig. 8. Step-wise formation of Cys-derived heterocycles. A, diagram of two step conversion of
cysteine to thiazole. First an ATP-dependent heterocyclase converts cysteine to thiazoline,
then an FMN-dependent hydrogenase oxidizes the thiazoline into thiazole. B, diagram of
conversion of two step conversion of serine to oxazole. First an ATP-dependent heterocyclase
converts cysteine to thiazoline, then an FMN-dependent hydrogenase oxidizes the thiazoline
into thiazole.

microcin B17 pathway (59, 64). However, in other systems, like BalA1, C- to N- terminal
processing can be observed(64) and in some systems, like thiamuracin, heterocycles can be
installed in a non-linear fashion (68). The level of promiscuity of the processing enzymes also
ranges greatly amongst specific pathways (30, 55, 56, 64). RiPP PTM enzymes from
cyanobacteria are known to have less stringent regio-, chemo-, and allo- specificity due to the
fact that several hypervariable precursor peptide cores are often present in the gene cluster and
are each post-translationally modified (19, 29, 58, 66, 69). For example, the cyclodehydratase
PatD, involved in patallemide synthesis, has been shown to modify cysteines to thiazolines in
many core sequence contexts and lengths just as long as the C-terminal region of the leader
peptide is present (70). However, this promiscuity comes at a cost as PatD is slow in converting
thiazolines onto cysteines, especially on non-native cores. Conversely, the cyclodehydratase and
dehydrogenase in microcin B17 synthesis have rather tight specificity. When mutations are made
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Fig. 9. Comparison of biosynthetic gene clusters for various. Precursor peptide is represented in black.
Precursor peptide recognition peptide is depicted in red. Cyclodehydratase genes are shown in blue,
dehydrogenase genes are shown in yellow, and all other genes not necessary for heterocycle formation
are shown in gray.

to heterocycle flanking residues in the microcin B17 precursor peptide, then azole formation is
thwarted (60). The hakacin biosynthetic gene cluster encodes two precursor peptides BalhA1 and
BalhA2, similar to cyanobacteria systems (64). This suggests that the heterocycle installing
enzymes would be required to be more permissive. In previous studies it was shown that the
cyclodehydratase in the hakacin pathway is very efficient at modifying a scrambled BalHA1 core
and the microcin B17 core, but that the residue C40 in the leader region of the hakacin precursor
peptide is necessary (64).
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There are thus no definitive rules for enzyme assembly and processing mechanics for
TOMM proteins, and so these systems must be studied independently. As a consequence, many
pathway-specific details remain elusive. In some cases, like Microcin B17, the cyclodehydratase,
precursor recognition protein and dehydrogenase have been found to form a complex (32, 60). In
TOMM systems there is the potential to mix and match different cyclodehyratases,
dehydrogenases, and precursor peptide recognition proteins in order to maximize the number of
novel peptides that can be generated. Therefore, evaluating how these enzymes work together
(whether in a complex or alone) is important. When diverse noncognate dehydrogenases
replaced the cognate dehydrogenase in Microcin B17 synthesis, they were not capable of
oxidizing any heterocycles (56). This is perhaps a result of the inability of these new
dehydrogenases to form a functional complex with the cyclodehydratase and precursor
recognition protein. However, in other pathways such as the BalhA1, BalhD (dehydrogenase)
was able to act in isolation to install azoles regardless of the presence of BalhC (precursor
peptide recognition protein) or BalhB (cyclodehydratases). In addition, non-native
dehydrogenases were able to be exchanged for the native dehydrogenase in the hakacin pathway
with thiazoles being formed (56). Many details of how the heterocycle-forming enzymes work
together in the micrococcin are unknown. This reinforces the remarkably variable nature of these
systems and how each system’s properties must be characterized on an individual basis.
1.5 Summary of subsequent chapters
This thesis evaluates the use of RiPP biosynthetic systems and their use in engineering
novel peptides. It focuses on two different peptide systems: the lasso peptide microcin J25 and
the thiopeptide micrococcin. In chapter two I explore the use of microcin J25 as a peptide
scaffold for the discovery of novel antimicrobial peptides through an in vivo high-throughput
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screen. Then, in the last chapter I explore the system specific protein-protein interactions
between micrococcin heterocycle installing proteins TclI, TclJ, and TclN with the hope that in
future the crucial components of heterocycle formation can be used to generate novel peptides.
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CHAPTER 2: Lasso peptides as scaffolds for a high throughput screen of novel antimicrobial
peptides
2.1 Introduction
Lasso peptides as peptide scaffolds
Lasso peptides are a family of RiPPs that hold great potential as scaffolds for novel
peptide generation. One of the most well-studied yet biosynthetically simple lasso peptides is
microcin J25 (MccJ25). MccJ25 possesses antimicrobial activity and is plasmid-encoded in
certain Escherichia coli strains. Its biosynthetic gene cluster consists of four genes: mcjA, mcjB,
mcjC and mcjD. The gene mcjA encodes the precursor peptide, while mcjB/C encode the two
proteins that comprise the enzymatic knot-tying complex responsible for modifying the precursor
peptide (1, 32). McjB acts like an ATP-dependent cysteine protease, cleaving the leader peptide
from the core and McjC is involved in the formation of the ring (37). The MccJ25 precursor
peptide (McjA) is 58 amino acids long, with a 37- amino acid N-terminal leader peptide and a
21-amino acid C-terminal core peptide (37). A linkage between Glu8 and Gly1 forms the 8amino acid ring of the lasso peptide while the bulky side chains of Phe19 and Tyr20 provide the
steric hindrance necessary to keep the loop in place (37, 71, 72) (Fig. 10).
Previous research has shown that the loop region of MccJ25 can be varied considerably
and still be recognized by the knot-tying machinery. This possibility for variability makes lasso
peptides ideal for bioengineering. For example, one study created all possible single amino acid
substitutions in all positions of the 21-amino acid core peptide excluding Glu8 (one of the amino
acids involved directly in ring formation) (Fig. 11) (1). They found that most of the positions of
the core peptide, except Gly1, Gly2, Glu8, Phe19, and Tyr20, were able to tolerate various
changes to the amino acid sequence while still producing a stable, mature, and exported lasso
peptide (73). Several of these positions in the core peptide were able to tolerate over fifteen
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different amino acid substitutions. This illustrates that there is a lot of flexibility allowed in the
amino acid sequence of the loop region. Lastly, another study investigated the effect that various
3-amino acid substitutions in the loop region of the core peptide had on the function of MccJ25.
They found that over half of the mutants retained their function (74). This flexibility was further
confirmed when three amino acids in the loop region of MccJ25 were swapped out for an
integrin binding motif Arg-Gly-Asp (RGD) in order to generate an MccJ25-RGD mutant that
was capable of inhibiting integrin, a potential target for cancer therapy (38, 39). The resulting
peptide was successfully converted into an integrin antagonist with nanomolar effectiveness.
This demonstrates that lasso peptides can be bioengineered into compounds with
pharmacological properties. It has also been shown that you can shorten the loop region and
extend the C-terminal tail below the ring without altering the lasso structure (71). All of this past
research highlights the vast potential MccJ25 has to be modified and its ability to be used to
create novel lasso peptides.
Massively parallel screening for bioactivity of randomized RiPPs in vivo
MccJ25 seems to possess the flexibility to be modified to produce thousands of unique
lasso structures. In addition, like many RiPPs it possesses antimicrobial activity. Due to the
increase of antibiotic resistant bacteria, development of novel antimicrobial peptides is ideal.
However, one problem when generating thousands of novel peptides is that only a few would be
expected to exhibit antimicrobial activity. Therefore, it is necessary to be able to screen through
vast numbers of peptides for those that appear to be toxic. We have developed a method to
screen through hundreds of thousands of peptides using massively parallel peptide activity
screening (MPAS) (Fig. 12). The basis of this platform is to generate a library of hundreds of
thousands of variant peptides in a plasmid-based inducible expression system. Random-insert
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Fig. 10. Microcin J25 biosynthesis. A, Microcin J25 biosynthetic gene
cluster. B, Simple diagram depicting the microcin J25 maturation
pathway.

Fig. 11. Single amino acid mutation study of McJA from Pavlova, et al.
Researchers in Pavlova’s group performed 380 single-amino acid substitutions.
Amino acid noted in the bars are tolerated mutations for production, maturation and
export of MccJ25. The native sequence of McjA core is shown below the chart. (1)
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plasmids are transformed into E. coli cells to create a library, where each clone is effectively
‘assigned’ to produce only one peptide variant. As a result, the E. coli library contains thousands
of different peptide variants. Once the library is created, it is mixed and grown under conditions
with or without inducer, turning on or off the expression of the potential antimicrobial peptides.
Next, Illumina sequencing is performed to obtain DNA sequence data for surviving peptideencoding plasmids. When a cell is assigned a toxic peptide, it will be depleted in the population,
eventually causing the DNA sequence for that peptide to be lost from the culture. By comparing
the sequences of the induced culture to the un-induced culture, one can identify many potentially
toxic peptides, or “hits”, by looking for peptide-encoding sequences that are depleted in the
induced culture compared to the un-induced. In our lab, we have carried out proof-of-principle
work using this MPAS platform on a linear peptide library and obtained hundreds of hits.

Fig. 12. Overview of massively parallel activity screening (MPAS). See text for more details.
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In order to perform the future screen to generate non-linear peptides based on RiPP
scaffolds (such as a lasso peptide scaffold), an inducible plasmid system must first be developed
which allows expression of variant peptides. It is important that the inducible system is
extremely tightly controlled so that there is next to no expression of the peptides when
uninduced. This is desirable because the peptides that are of the greatest interest are those that
will kill the cell. Therefore, if the system is too leaky then we may get antimicrobial peptide
activity in un-induced conditions particularly if a peptide is especially toxic, making it difficult
for us to identify those highly sought-after toxic peptides. We discuss below a system in which
microcin J25 can be used as a scaffold to generate thousands of novel lasso peptides that can
then be screened for antimicrobial activity by MPAS methods. We evaluate the strength and
tightness of six different E. coli-derived promoters as well as develop a two-plasmid system for
lasso peptide expression using molecular cloning techniques.
2.2 Experimental Methods
Strains and culture conditions
The bacterial strains and plasmids used in this chapter can be found in Tables 2 and 3.
Plasmids were constructed and maintained in Escherichia coli strain DH5α. For growth curves,
strains were either based in DH5α or MDS™42 Meta ΔrecA E. coli (Scarab genomics). All
bacterial cultures were grown in Luria broth (LB: per liter, 10 g Bacto tryptone, 5 g Bacto yeast
extract, 5 g NaCl, 1 ml 2N NaOH) or minimal defined media (MDM: 0.06 M NaCl, 0.01 M
KH2PO4, 0.01 M NH4Cl, 0.5% glycerol, 0.002 M MgSO4, 0.02 mL 10mM CaCl2, 0.2 ml Trace
minerals (200 ml H2O, 400 mg EDTA, 300 mg FeSO4, 50 mg MnSO4, 50 mg ZnSO4, 25 mg
H3BO3, 25 mg CoCl2, 5 mg Na2MoO4, 5 mg CuSO4). Antibiotics used were kanamycin (30
mg/ml) and chloramphenicol (30 mg/ml). Cultures were induced for protein expression using 0.3

24

mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 0.3% L-rhamnose, 0.3% L-arabinose, or 0.4
μM anhydrotetracycline (ATc).
Plasmid construction
The mcj genes were synthesized with codon optimization for expression in E. coli.
Plasmid construction was carried out using standard molecular cloning procedures. Annotated
vector and insert sequence files are given in supporting information file. Complete vector
sequences are given in the Supplementary Information. Plasmids and strains employed in this
study are given in Supplementary Table 1 and 2.
Fluorescent assays
Cultures of promoter strains were grown overnight and subsequently 20 µl were used to
inoculate 4 ml LB cultures. These cultures were grown with and without inducer for 8 hours.
Optical density of the cultures was measured at 600 nm (OD600). Cultures were then diluted in
LB and normalized to the lowest OD600. Arbitrary fluorescent units (AFU) were determined by
reading a white polystyrene 96-well plate on a BioTek plate reader at 509 nm. Final AFU values
were normalized to vector-only and blank LB controls.
Miller assays
Strains were grown in LB with and without inducer for approximately 4 hours. Then
OD600 measurements were recorded for individual cultures. For each assay, 600 µl of β-Gal
master mix consisting of 600 µl Basal Buffer (Basal Buffer: 500 ml H2O, 4.3 g Na2HPO4, 2.4 g
NaH2PO4, 0.75 g KCl, pH to 7.0 with about 1.5 ml 2N KOH, 1 ml 1M MgSO4_7H2O, 1 ml of
CHCl3), 0.5 mg ortho-Nitrophenyl-β-galactosidase (ONPG), 0.5 µl 10% sodium dodecyl sulfate
(SDS), 3 µl β-mercaptoethanol (BME), 50 µl chloroform, and diluted culture were combined and
timer was started. Samples were incubated at 32°C until bright yellow color was observed in 1 or
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more samples. Stop buffer (1M Na2CO3 with 1 ml CHCl3) was added to stop reactions. Samples
were then vortexed and centrifuged to pellet chloroform and other cellular debris. OD420
measurements were taken and Miller units were calculated using the equation
(1000*OD420)/(OD600*t*v) where t= assay time in minutes, v=volume of cells added in ml
corrected for the dilution factor that was performed.
Growth curves
Strains were grown overnight, then a 20 µl sample was used to inoculate 4 ml cultures of
either LB (Fig 14BC) or MDM (Fig. 14B) with and without their appropriate inducers and with
antibiotics. Then OD600 measurements were taken at specific time points using a
spectrophotometer.
2. 3 Results
Promoter optimization
There are various options in choosing an inducible promoter for vector expression
systems. For our MPAS experiments we wanted an inducible promoter with extremely low
background activity when uninduced, but that also yields high expression when induced.
Therefore, we evaluated the expression profile of several common E. coli-derived promoters:
ParaBAD, PrhaBAD, two variations on Plac (PlacT5(lacIWT), PlacT5 (lacIq)), and Ptet (Fig 13). The two
different lacT5 promoters vary in the constitutive promoter region of the lac repressor (LacI).
PlacT5 (lacIq) has an altered -35 region which makes it more canonical which should increase
expression of the repressor. We tested each promoter in the context of two different reporters: βgalactosidase (originally encoded by the gene lacZ of the lac operon) and monomeric
superfolder green fluorescent protein (msfGFP). First, in the data from the Miller assay
measuring β-galactosidase, we see that PrhaBAD and the two lac promoters appear to give the
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lowest amount of background uninduced expression while still leading to a large amount of
expression when induced (Fig. 13F). Considering the fluorescent data control of expression for
PrhaBAD is extremely tight yet very strong (Fig. 13G). By fluorescence-based assay, the lacT5
promoters yield very low expression of msfGFP while giving the most background expression
when uninduced. Interestingly, the Ptet promoter shines as being a very strong promoter with low
uninduced expression when fluorescence is measured. ParaBAD is arguably the leakiest and least
strong promoter of the group.
A synthetic inducible MccJ25 expression system
We wanted to develop a two-plasmid system with distinct promoters in order to
selectively turn on expression of either the precursor peptide McjA or the modifying enzymes
McjBC or both. From the promoter data, PrhaBAD and Ptet promoters were chosen to express McjA
and McjBC respectively. While MccJ25 does originate from a single E. coli plasmid we wanted
to confirm that our two-plasmid based system still yielded functional MccJ25. When McjA and
McjBC were co-expressed, cultures did not appear to grow compared to control strains (Fig.
14A). This is indicative that microcin J25 is being produced and its antimicrobial activity is
killing the cells. More detailed growth curves confirm that when expression of all three Mcj
proteins is induced, growth of cultures is inhibited compared to uninduced and control strains
(Fig. 14BC). This also confirms that our promoters are tight because we are getting normal
growth when uninduced.
Preparing McjA for easy core peptide randomization
In future MPAS experiments the core region of McjA will be randomized. In order to make
future cloning steps easier we wanted to add a unique BamHI site into the beginning of the core
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Fig. 13. Promoter optimization for E. coli expression. Inducible promoters. lacI, araC, rhaR, rhaS, and
tetR all encode regulatory proteins. These regulatory proteins bind to operating sites indicated by Ox.
Promoters are indicated by right angled arrows above genes. CAP represents the CAP/cAMP binding
site. RNA polymerase recognition sequence is represented as the -35/-10 region. A, Lac operon. B,
arabinose operon. C, rhamnose operon. D, tet operon E, Lac T5 promoter F, Results from Miller assay
on promoter strains driving the production of β-galatosidase. Each condition for individual strains was
done in triplicate and in LB. Plasmids were in DH5α. F, Results from Miller assay on promoter strains
driving the production of β-galatosidase. Each condition for individual strains was done in triplicate and
in LB. Strains were in DH5α. G, Results from fluorescent assay on promoter strains driving the
production of msfGFP. Each condition for individual strains was done in triplicate and in LB. Strains
were in DH5α.
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Fig. 14. Reconstitution of MccJ25 expression in E. coli. A, picture of induced
cultures in MDM after 24hrs of growth. When McjABC are co-expressed growth is
inhibited. B, growth curve of uninduced cultures in LB. C, growth curve of induced
cultures in LB.
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(Fig. 15A). This would allow us to easily switch in and out new core sequences. Altering the core
to include a BamHI site causes an alanine to serine mutation on the third residue in the core
region of McjA. Although we believed that this mutation would be tolerated based on previously
described data (Fig. 11) (1), we wanted to confirm this to be true. Growth curves performed with
the expressed altered McjA in conjunction with McjBC indicated that active MccJ25 was being
created compared to the uninduced and vectors only strain control (Fig. 15B).

Fig. 15. Altering the McjA core peptide to accommodate a unique BamHI site. A,
graphical representation of where the BamHI site wlll be inserted into the core and the
subsequent mutation it will cause. B, Growth curves confirming production of MccJ25
with altered core including BamHI site. Cultures were grown in MDM.

2.4 Discussion
In future, a small lasso peptide library of hundreds of thousands of clones could be
generated by randomizing a nine amino acid section of the loop region of MccJ25. The loop
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region can be randomized by genetically modifying mcjA (Fig. 16A). The library insert
randomizes the amino acids from tyrosine to isoleucine (Y9 to I17) in the core portion of the
peptide. The nucleotide sequence of the random region of the loop is VVTNHTVVTNHTVVT
NHTVVTNHTVVT (Fig. 16B). This sequence avoids getting peptides that possess long string of
hydrophobic amino acids. Long strings of hydrophobic amino acids are naturally more
antimicrobial due to their ability to disrupt cell membranes. We want to avoid these peptides
because we want to generate peptides with potentially novel and specific mechanisms of action.
This sequence also avoids any stop codons and allows for a variety of charged, polar and
nonpolar amino acids. The plasmid containing the modified mcjA would be transformed into a
strain of E. coli which has already been transformed with the plasmid containing the modifying
enzymes. Clones would then be selected on LB without inducer and combined into a mixed
population for subsequent MPAS experiments.
Some of the hits generated from the MPAS experiment indicating that a peptide is toxic
would subsequently need to be confirmed as toxic and assessed for lasso-ization by McjB or
McjC. This lasso formation could be assessed by either mass spectrometry or potentially simple
gel-shift analysis. When gel electrophoresis is performed, there should be a characteristic band
shift when the precursor peptide gets cleaved by McjB. The strep-GB1 tag is located on the Nterminus of the precursor peptide, and the cleaved leader peptide is missing the 21 amino acid
core peptide (2.1 kDa loss) which should lead to a shift in the gel. This method assumes that if
McjB is capable of recognizing and cleaving the precursor peptide then McjC should be able to
modify the core to produce the lasso peptide. This system is ready to be used in an MPAS
experiment and library insert oligos have been purchased; however, MPAS technology was
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being further validated using linear peptides for the second time and I moved onto work that will
be presented in Chapter 3.

Fig. 16. Lasso Peptide Library Design. A, Detailed description of the exact region of the McjA core that
will be randomized. B, Chart illustrates which amino acids are allowed with NHT and VVT. Allowed amino
acids are shown in the table with the checkmark below while amino acids that are not allowed are present
in the box with the x below. VVTNHT allows for various amino acids, but eliminates the ability to have a
long string of hydrophobic amino acids in a row or any stop codons.
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CHAPTER 3: Mapping interactions between micrococcin biosynthetic enzymes
Devan M Bursey1, Kathryn D Bewley2, Philip R Bennallack1, Susan S Miller2, Joel S Griffitts1
1

Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT
84602 and 2Department of Pharmaceutical Chemistry, University of California, San Francisco,
CA 94143
3.1 Abstract
Thiopeptides are bacterially produced bioactive compounds derived from ribosomally
synthesized peptides that are extensively post-translationally modified. We have recently
elucidated the biosynthetic pathway for the antibacterial thiopeptide micrococcin. This pathway
is initiated when six Cys residues in the TclE precursor peptide are converted to heterocyclic
thiazoles, through the action of the ATP-dependent cyclodehydratase enzyme TclJ (to form
thiazolines), followed by the FMN-dependent dehydrogenase TclN (to form thiazoles). A nonenzymatic protein, TclI, is involved in heterocycle formation; however, its exact role has been
unclear. Here we employ structural modeling and biochemical co-purification methods to
investigate TclI as an adaptor protein that couples the TclJ and TclN enzyme to the TclE
substrate peptide. TclI appears to be a two-domain protein, with the N-terminus binding to TclE
and the C-terminus binding to TclJ and TclN. TclI binds to each of its three partners through
independent interaction surfaces. We also show that an N-terminal portion of TclJ, in isolation,
can associate with TclI.
3.2 Introduction
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are
microbially produced natural products that are initially synthesized on the ribosome, and
subsequently decorated with numerous post-translational modifications (PTMs) to yield
bioactive compounds (33, 35). RiPP precursor peptides generally contain an N-terminal leader
sequence involved in recruitment of the enzymes that carry out PTM installation, as well as a C33

terminal “core peptide” region that is the site of the modifications. The final step in RiPP
biosynthesis often involves removal of the leader peptide from the modified core. Conversion of
core peptide Cys, Ser, and Thr residues to azolines, and their subsequent oxidation to azoles are
common steps in RiPP biosynthesis, particularly for cyanobactins (e.g. patallamide and
trunkamide), linear azol(in)e containing peptides (LAPs) (e.g. microcin B17 and streptolysin),
and thiopeptides (e.g. thiomuracin, and micrococcin) (28, 47, 50). Thiopeptides constitute a large
RiPP family with over 100 known members possessing diverse biological activities, including
antimicrobial functions (41, 43). A typical thiopeptide contains several azol(in)e structures, with
Cys-derived thiazoles being most prominent. Thiopeptides also feature at least one macrocycle
anchored by a six-membered nitrogenous ring derived from dehydroamino acids such as
dehydroalanine (41, 43, 44). Thiopeptides may also contain other diverse modifications,
including C-terminal decarboxylation (micrococcin (46)), methylation (nocardithiocin (75)),
hydroxylation(thiocillin (76), nosiheptide (77)), and glycosylation (thiazomycin (78),
glycothiohexide (53)).
The microccocin biosynthetic pathway
Microccocin was the first characterized thiopeptide produced by Bacillus and
Macrococcus sp. and its biosynthesis involves several PTMs including thiazoles, dehydroamino
acids, C-terminal decarboxylation, and formation of a pyridine ring (43, 45). The M. caseolyticus
micrococcin gene cluster is plasmid-encoded and consists of 12 tcl genes, suggesting that it is
simpler than the analogous gene cluster in Bacillus cereus ATCC (Fig 17A) (45). The
micrococcin precursor peptide TclE is divided into the 35 amino acid residue leader and the 14
amino acid core. Micrococcin biosynthesis begins with the chemical alteration of all six cysteine
residues present in the core of TclE to thiazoles. This conversion of Cys to thiazole licenses the
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core for subsequent modifications (Fig 17B) (42, 45). Each thiazole conversion is a two-step
process that necessitates the activity of three proteins: TclI, TclJ, and TclN (42, 45). First TclJ, a
Thiazole/Oxazole-Modified Microcin (TOMM) cyclodehytradase, alters cysteines to thiazolines
in an ATP-dependent manner (52, 53). Subsequently, TclN, an FMN-dependent TOMM
dehydrogenase, oxidizes the heterocycles to thiazoles (Fig 1C). TclI is a required non-enzymatic
auxiliary protein in the heterocycle forming process (48, 79).
TOMM biosynthetic genes are prevalent in many phyla of bacteria and as a result are
often genetically diverse (48). Therefore, the specific details of each biosynthetic pathway must
be elucidated individually. While the general function of these thiazole incorporating enzymes in
micrococcin synthesis is known, information on how these proteins in this system interact with
one another is still missing. In this paper, we investigate the general protein-protein architecture
of enzymes TclI, TclJ, TclN, and TclE in micrococcin biosynthesis, focusing on the predicted
role of TclI as a potential docking protein that interacts independently with TclJ, TclN and TclE.
We used a plasmid-based expression system in E. coli to study the interactions of TclIJNE
primarily by His6-TclI co-purification, SDS-PAGE and predicted structural modeling.
3.3 Experimental Procedures
Strains and culture conditions
The bacterial strains and plasmids used in this study are summarized in Tables S4 and S5
Plasmids were constructed and maintained in Escherichia coli strain DH5α. For protein
expression, plasmids were transformed into strain BL21, Nico 21 (DE3) or DH5α. All bacterial
cultures were grown in Luria broth (LB: per liter, 10 g Bacto tryptone, 5 g Bacto yeast extract, 5
g NaCl, 1 ml 2N NaOH). Antibiotics used were kanamycin 30 mg/ml, ampicillin 100 mg/ml, and
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Fig. 17. Micrococcin Synthesis. A, A map of the native tcl gene cluster from M. caseolyticus.
The gene encoding the precursor peptide (TclE) is colored black, and the genes encoding
proteins for thiazole installation (TclI, TclJ, TclN) are colored blue. Other essential proteins
for complete micrococcin production are shown in gray. Nonessential proteins are shown in
white. B, Overview of the micrococcin biosynthetic pathway, with TclE core peptide
modifications brought about by the thiazole installation machinery indicated in blue, and all
subsequent modifications indicated in gray. Abbreviations: Tz, thiazolyl; Dc, decarboxyl; Dh,
dehydro. C, Two-step conversion of TclE Cys residues to thiazole via TclI, TclJ, and TclN.
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chloramphenicol 30 mg/ml. Cultures were induced for protein expression using 0.3 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG).
Plasmid construction
The tcl genes were synthesized with codon optimization for expression in E. coli.
Plasmid construction was carried out using standard molecular cloning procedures. Annotated
vector and insert sequence files are given in supporting information file. Complete vector
sequences are given in the Supplementary Information. Plasmids and strains employed in this
study are given in Supplementary Table 3 and 4.
Tcl protein expression and purification
To prepare samples for SDS-PAGE analysis, overnight liquid cultures (4 ml) were grown
from single colonies in the presence of appropriate antibiotics. 100 ml cultures were inoculated
with 2 ml of overnight culture, allowed to grow at 30 °C for 1 h, followed by induction for
another 8 h at 30 °C. Cells were collected by centrifuging 50 ml of the culture, and cell pellets
were frozen at -80 °C for a minimum of 1 h. Cell pellets were then subjected to protein
purification with either Ni-NTA-linked (for the His6 tag) or glutathione-linked (for the GST tag)
resin.
For His6 purification cell pellets were thawed on ice and re-suspended in 1.5 ml of lysis
buffer (50 mM HEPES, 300 mM NaCl, 0.2 % Triton X-100, 0.5 mg/ml lysozyme, 40
mM imidazole, 1 mM EDTA). Lysis took place for 1 h at 4 °C. Then cell lysates were sonicated
2 × 20 sec at power 3 using a probe sonicator to ensure complete lysis. Samples were centrifuged
at 13,000 rpm for 9 min (4 °C) and approximately 1 ml of supernatant was transferred to a new
micro centrifuge tube. Supernatant was incubated end over end with 50 μl of NTA-nickle
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agarose beads at 4 °C for 30 min. Unless stated otherwise in figure legends the beads were
washed 3 × 1 ml wash buffer (60mM imidazole, 300 mM NaCl, 50 mM HEPES) and eluted in
50 μl of 2x SDS sample loading dye (20% glycerol, 83 mM Tri pH 6.8, 40 mg/ml sodium
dodecyl sulfate (SDS), 0.01% bromophenol blue, 0.03 μl/ml 2-mercaptoethanol).
For GST purifications cell pellets were thawed on ice and re-suspended in 1.2 ml lysis
buffer (GST buffer (50 mM Tris 8.0,150 mM NaCl), 0.5 mg/ml lysozyme, 2 mM EDTA, 0.2%
Triton X-100, 1/100 protease inhibitor (Sigma)). Cells were lysed at room temperature for 15
min then placed on ice where dithiothreitol (DTT) was added to a final concentration of 1.5 mM.
Samples were sonicated 2 × 20 sec at power level 3. Cell lysates were centrifuged at 13,000 rpm
at 4 °C for 9 min to pellet cell debris. Approximately 1 ml of supernatant was transferred to a
new microfuge tube. 50 μl of unwashed glutathione-agarose beads were added and samples were
rotated end over end for 45 min at 4 °C. Slurry was pelleted at 13,000 rpm for 10 seconds.
Supernatant was removed and beads were washed 3 × 1 ml GST buffer. GST buffer was
completely removed and proteins were eluted from resin in 75 μl of 2X SDS loading dye.
Purified samples were heated at 100°C for 2 min then centrifuged. Unless stated
otherwise 5 μl of supernatant was loaded onto a 12% resolving Laemmli gel with a 4% stacking
gel. Gels were run using 1x Laemmli running buffer and were stained overnight in coomassie
blue stain then destained before pictures were taken.
Mass spectrometry analysis of TclE processing
For purification of His tagged enzymes for mass spectrometry analysis 25 ml overnight
cultures were grown from single colonies. These overnight cultures were then used to inoculate 1
L growths (30 °C). After 1 h, IPTG was added and the cultures were grown for an additional 6
hours. The cells were harvested by centrifugation and the cell pellets were frozen at –80 ºC
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overnight. For co-purification of His6-TclIJ/His6-TclIN/His6-TclIJN the cells were then thawed
on ice with the addition of lysis buffer (50 mM HEPES, 150 mM NaCl, pH 7.8). A protease
inhibitor tablet (Roche), 0.2% Triton X-100 and 0.5 mg/ml lysozyme were added and the cells
were incubated on ice for 1 h. Complete lysis was achieved by sonication for 2 min on ice using
a Branson Sonifier 450, followed by centrifugation for 20 min at 32,539 × g. The supernatant
was incubated with 1 ml of Talon resin for 30 min at 4 °C. Resin was washed with 3 × 10 ml
lysis buffer, followed by elution with lysis buffer plus 75 mM imidazole (4 × 1 ml). The elution
fractions containing protein were buffer exchanged back into lysis buffer, concentrated and flash
frozen with 10% glycerol and stored at –80 ºC.
For purification of GST-tagged TclE, 30 ml cultures were inoculated with 1 mL
overnight culture, grown at 37°C until an OD600 = 0.6, then IPTG was added and the cells were
grown for an additional 20 hrs at 25°C. The cells were harvested via centrifugation and the cell
pellets were frozen at –80 ºC for at least 30 min. The cells were then thawed and resuspended in
1 ml lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 0.5 mg/ml lysozyme, 2 mM EDTA and one
Roche protease inhibitor tablet per 10 ml). Complete lysis was achieved after a 15-min
incubation at room temperature (RT) in lysis buffer, followed by addition of 1.5 mM
dithiothreitol (DTT) and several short sonication pulses with a microtip. The disrupted cells were
pelleted at 7,000 × g to remove insoluble material and the supernatant was combined with 30 µl
of glutathione-agarose resin (slurry) at 4 ºC for 45 min (rotating). The resin was pelleted and the
beads were washed with 50 mM Tris pH 8, 150 mM NaCl three times and the peptide was eluted
with 40 µl buffer plus 10 mM reduced glutathione. The eluant was either frozen at –80 ºC for
later use, or directly treated with tobacco etch virus (TEV) protease and ZipTipped (using the
manufacturer’s instructions.)
39

Activity of Tcl enzymes was tested in vitro. 20 μl reactions containing 20 mM GST-TclE,
5 mM DTT, 2 mM ATP, 20 mM MgCl2, 1 mM enzymes, and 1 mg TEV protease, were allowed
to react for 40 min at RT. Reactions were zip-tipped (using the manufacturer’s instructions) and
analyzed by matrix assisted laser desorption ionization-time of flight mass spectrometry
(MALDI-TOF) abbbreviation MS.
Modeling of Tcl protein structures
Sequences for TclI, TclJ, and TclN were submitted online to the I-TASSER (Iterative
Threading ASSEmbly Refinement) server (80) to predict protein structure. The models with the
highest C-score were chosen for each Tcl protein. The top-ranked PDB structural analogs for
each each Tcl protein (4BS9, 3E07) were used as a comparative reference. The structural models
and reference models .pdb files were downloaded and viewed in USF Chimera(81).
3.4 Results
Functional Tcl proteins can be expressed in E. coli
While an expression system for tcl genes has been described previously in B. subtilis, for
simple analysis of the microccocin biosynthetic pathway we wanted to develop a system to
express functional Tcl proteins in the gram-negative E. coli. In this change of systems, we
wanted to first confirm that our engineered Tcl proteins were capable of being expressed in E.
coli. Testing for expression necessitated the ability to be able to purify each protein. Thus, TclE,
TclI, TclJ, and TclN were engineered with affinity tags based on previously published results in
which the functionality and expression of each protein was tested after the inclusion of an N- or
C-terminal affinity tag in B. subtilus(46). Bands corresponding to the correct molecular weight of
TclE, TclI, TclJ, TclN appear on a gel when they are individually expressed and affinity purified.
All of these bands are absent in the lanes of the control strains, which verifies that all Tcl
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Fig. 18. Functional expression and purification of thiazole installation proteins from E. coli. A,
Maps of plasmids used to express affinity-tagged Tcl proteins. Plasmid names are according to
the inserted affinity-tagged Tcl protein. Locations of His6 or GST tags are indicated in gray. Genes
encoding Tcl proteins are color coded consistent with other figures in this report. B, SDS-PAGE
analysis with coomassie blue staining to detect Tcl protein expression and purification. Whether
proteins were purified with nickel-NTA (His6 pull-down) or glutathione-linked (GST pull-down)
resins is indicated. M, molecular weight markers; asterisks indicate tagged Tcl proteins,
determined by expected molecular weight and comparison to the empty vector lane. C, MS
analysis (MALDI-TOF) of thiazole installation on TclE using purified components from E. coli.
Reactions included TEV protease to cleave the leader-core region of TclE from the GST tag prior
to mass analysis. The modified N-terminus of TclE (after TEV cleavage) is (GGSEFQT...). See
Fig. 5C for the complete TclE peptide sequence.
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proteins are capable of being expressed under our conditions (Fig. 18AB).
Although we were able to detect our expressed proteins, it remained unclear whether or
not our engineered proteins were functional. To determine whether or not the Tcl proteins were
functional we evaluated the conversion of cysteines to heterocycles in the core of TclE in the
presence of Tcl proteins purified from E. coli. A major peak corresponding to 6-thiazolines was
observed when TclI and TclJ where incubated with TclE. A minor peak representing the near
complete 5-thiazolines product was also evident suggesting that in our reaction conditions TclJ
was capable of catalyzing complete and near complete conversion to thiazolines in the presence
of TclI. TclE in the presence of TclI and TclN appeared the same as the unmodified version. This
is because TclN requires pre-existing thiazolines, which are formed by TclJ, as substrate. When
TclI, TclN, TclJ, and TclE were incubated together the data showed complete conversion to 6thiazoles compared to the control (Fig. 18C). This demonstrated that all proteins were functional
in vitro.
TclI acts as a scaffolding protein in a TclIJNE complex
Analysis of the biosynthetic gene cluster for microcin B17 indicated that a trimeric
complex formed containing a cyclodehydratase, a dehydrogenase, and a docking protein (47, 60).
As a result, it is believed that many TOMM biosynthetic enzymes form a complex, although in
many cases co-purification data is lacking as typically each protein is individually expressed then
combined together in vitro (82). To determine if TclIJNE form a complex, we co-expressed all
four proteins, with TclI possessing a His6 affinity tag (Fig. 19A). After purification of TclI, we
were able to see three co-purifying bands that appear to be TclJ, TclN and TclE (Fig. 19B).
When the His6 tag is removed from TclI and the experiment is repeated, all four bands disappear,
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Fig. 19. TclI as a central docking protein in the TclEIJN complex. A, Maps of plasmid used in the twoplasmid and one-plasmid analyses indicated in (B). These maps are rendered similarly to those shown in
Fig. 2A. B, SDS-PAGE analysis with coomassie blue staining to detect Tcl protein expression and copurification. Asterisks indicate Tcl proteins that co-purified with His6-tagged TclI. C, a model depicting the
connectivity between Tcl proteins during thiazole installation.
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indicating that the inducibly expressed Tcl proteins do not bind to nickel-NTA resin beads nonspecifically in our system. Our data show that a four membered TclIJNE complex is readily copurified.
The general architecture of the TclIJNE protein complex was unclear. The Tcl proteins
could interact in many different combinations (Fig. 20). TclI exhibits no enzymatic activity and
can be used to isolate the TclIJNE complex; therefore, we predict it plays an important role as
the scaffolding protein for this complex. We were interested in characterizing the binding
partners of TclI. It is possible that TclI could bind directly to one, two or all of the proteins in the
complex. We expressed TclI, TclJ, and TclN each individually with His6-TclI (Fig 3A). TclJ,
TclN, and TclE each co-purify independently with TclI (Fig. 3B), leading us to conclude that
TclI has three unique interaction surfaces and plays a key role in bringing together the TclJ and
TclN enzymes with their substrate. (Fig. 19C).
Predicted structural models
With evidence for a general model in which TclI interacts with TclE, TclJ, and TclN
across three separate surfaces we wished to consult structural models of the proteins when
making further predictions of the architecture of this complex. Unfortunately, the structures for
Tcl proteins are unknown; therefore, we generated predicted structures using an online protein
modeler. Interestingly, both the TclI and TclJ models most closely resembled two separate
domains of the single polypeptide TruD (PDB:4BS9) (83). TruD is a cyanobactin heterocylase in
the trunkamide pathway (Fig. 21A). TclI appears most similarly to the N-terminal domain (NTD)
of TruD while TclJ parallels the C-terminal domain (CTD) of TruD. In addition, the N-terminal
domain of TclI appears to have an N-terminal winged-helix-turn-helix structure characteristic of
a RiPP precursor peptide recognition element (RRE) (35, 54). The putative TclN model showed
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Fig. 20. Hypothetical TclIJN complex models. Simple depiction of some
of the different combinations TclIJN could interact to form a complex.

Fig. 21. Structural models for TclI, TclJ, and TclN. A, Predicted I-TASSER models for TclI and
TclJ compared to TruD a cyclodehydratase fromthe trunkamide A pathway. Dashed lines
represent regions of potential homology. B, Predicted I-TASSER model for TclN compared to a
putative nitroreductase from cyanobacteria. Dashed lines represent regions of potential
homology.
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the highest similarity with a cyanobactin nitroreductase (3EO7) (Fig. 21B), which folds into a
single globular domain.
Further characterization of TclI interaction surfaces with TclJ, TclN, and TclE
Based on analysis of the predicted structural models we hypothesized that due to the
presence of the RRE in the NTD of TclI it should bind to the leader of TclE. In comparison to
TruD, it appears perhaps that the CTD of TclI interacts with TclJ. We postulated that TclN might
also interact with the CTD of TclI. Co-purification of TclJ, TclN, TclE and TclEleader with the
affinity tagged NTD or CTD of TclI were performed to evaluate these predictions. TclE does copurify with TclINTD, and TclINTD appears to be stabilized in the presence of TclE compared to the
control (Fig. 22A). However, it should be noted that when TclE and TclINTD are co-expressed, cells
grow much slower compared to when TclE is absent, requiring six times the amount of cell culture
to reach the same pellet density as all other cultures. Consistent with these observations, TclE does
not appear to be pulled down with the TclICTD confirming that TclE appears to bind specifically to
the NTD of TclI. Furthermore, TclEleader is sufficient for binding to TclINTD (Fig. 22B). In addition,
our results support a model in which TclICTD is capable of binding to both TclJ and TclN, since
bands representing the correct molecular weight for TclJ and TclN appear when they are coexpressed with the CTD of TclI compared to control strains where TclN and TclJ are absent(Fig.
22A). Structural models for both TclJ and TclI closely resemble TruD. TclJ shows similarity to the
CTD of TruD while TclI is similar to the NTD of TruD (Fig. 21). Therefore, we hypothesized that
the CTD of TclJ is the region of the protein that binds to TclI. To test this, two versions of the
TclJNTD were co-expressed with His6-TclI. From the data, it appears that the NTD of TclJ is
adequate for binding to full length TclI (Fig. 22C). Combining this data with our previous data we
suggest that the N-terminal domain of TclJ interacts through a surface on the CTD of TclI.

46

Fig. 22. Domain analysis of TclI binding to TclJ, N, and E. A, Simple diagram of His6-TclINTD and His6TclICTD compared to native TclI. SDS-PAGE analysis with coomassie blue staining to detect Tcl protein
expression and co-purification. Asterisks indicate His6-TclINTD and Tcl proteins that co-purified with His6tagged TclINTD/TclICTD B, Diagram of the two NTD versions of TclJ used. SDS-PAGE analysis with
coomassie blue staining to detect Tcl protein expression and co-purification. Asterisks indicate TclJ
proteins that co-purified with His6-tagged TclI. C, Diagram of GST-TclEfull and GST-TclEleader. SDSPAGE analysis with coomassie blue staining to detect Tcl protein expression and co-purification.
Asterisks indicate His6-TclINTD and Tcl proteins that co-purified with His6-tagged TclINTD. 55 mM
Imidazole, Ni (NTA) beads washed twice D, a more detailed model for how TclI, TclJ, TclN and TclE
interact with each other.
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3.5 Discussion
We have confirmed that TclIJNE combine to form a four membered complex, and based
on the findings in this paper, we have proposed a more detailed model for how these four
proteins interact (Fig. 22D). In this model TclI, while not possessing any known enzymatic
activity, is the central scaffolding protein for this thiazole installing complex. TclI NTD interacts
with the leader region of the precursor peptide TclE. The NTD of TclI is where the RiPP
precursor peptide recognition element is (RRE) is proposed to be, therefore it is not surprising
that TclE interacts with TclINTD. TclEleader is sufficient for binding to the NTD of TclI. This
corroborates work that has been done with LynD, NisB, and McbB (35, 54). However, our data
also suggests that having the core peptide present stabilized the NTD of TclI. TclI binding to
TclE most likely positions TclE in a way that directs the core towards modifying enzymes, TclJ
and TclN. In our model, the NTD of TclJ binds to the CTD of TclI. It is interesting that TclJ and
TclI both mapped to TruD. This lends support to previous research which has described that in
approximately half known TOMM biosynthetic gene clusters the cyclodehydratase is fused with
an auxiliary protein (30, 47, 52). Most research on TOMM biosynthetic gene clusters focus on
the cyclodehydratases while dehydrogenases have been characterized less (48, 52, 53, 56). With
the lack of information on dehydrogenases and the limited structural models we proposed that
TclN bound to the CTD of TclI due to the fact that the NTD contains primarily the RRE. In our
co-purification experiments we did see that the CTD of TclI was sufficient to bind TclN. Work
should continue to be done to determine specific amino acid residues that are required on the
interaction surfaces of all proteins in the TclIJNE complex. A greater understanding of TOMM
protein complex architecture in micrococcin synthesis as well as other RiPP biosynthetic
pathways can be useful for future endeavors to generate novel combinatorial peptides by
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potentially allowing researchers to mix and match various cyclodehydratases, dehydrogenases
and RRE-containing auxiliary proteins.
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SUPPLEMENTARY INFORMATION
CHAPTER 2: Vector sequences
Parent Vectors
Plasmid features:
Multiple Cloning Site
ColE1 ori
LacZ ORF
KanR ORF
RhaR ORF
RhaS ORF
RhaBAD promoter
P15A ori
TetR ORG
Tet promoter
CmR ORF
pJG744
GAATTCccaCTCGAGccaGGTACCaccTCTAGAcccGTCGACaccAAGCTTccaCTGCAGccaGAGCTCg
gctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgCTGCtggttcgctcataagtaaaa
aacggcacctggtgccgtttttttgtctgaaacaagctgagcaataactagcataaccccttggggcctc
taaacgggtcttgaggggttttttgctgaaaggaggaactatatccggattggcgaatgggacgcgccct
gtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccct
agcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctcta
aatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagg
gtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgtt
ctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgattta
taagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaatt
ttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgcgcggaacccctatttgt
ttatttttctaaatacattcaaatatgtatccgctcatgaattaattcTTAGAAAAACTCATCGAGCATC
AAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATG
AAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCG
TCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGA
GTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGC
CATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAG
ACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACT
GCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGG
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GGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCAT
AAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGT
TTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACAT
TATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTAGAGCAAGA
CGTTTCCCGTTGAATATGGCTCATaacaccccttgtattactgtttatgtaagcagacagttttattgtt
catgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaagga
tcttcTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGG
TGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGAT
ACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACA
TACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGG
ACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAG
CTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCC
GAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTC
CAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTT
GTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAaacgccagcaacgcggcctttttacggttcctggcc
ttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccg
cctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggaagc
ggaagagcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcaatggtgcactc
tcagtacaatctgctctgatgccgcatagttaagccagtatacactccgctatcgctacgtgactgggtc
atggctgcgccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccg
cttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacg
cgcgaggcagctgcggtaaagctcatcagcgtggtcgtgaagcgattcacagatgtctgcctgttcatcc
gcgtccagctcgttgagtttctccagaagcgttaatgtctggcttctgataaagcgggccatgttaaggg
cggttttttcctgtttggtcactgatgcctccgtgtaagggggatttctgttcatgggggtaatgatacc
gatgaaacgagagaggatgctcacgatacgggttactgatgatgaacatgcccggttactggaacgttgt
gagggtaaacaactggcggtatggatgcggcgggaccagagaaaaatcactcagggtcaatgccagcgct
tcgttaatacagatgtaggtgttccacagggtagccagcagcatcctgcgatgcagatccg

pJG747
GAATTCccaCTCGAGccaGGTACCacaggaaacagctATGACCATGATTACGGATTCACTGGCCGTCGTT
TTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCG
CCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGA
ATGGCGCTTTGCCTGGTTTCCGGCACCAGAAGCGGTGCCGGAAAGCTGGCTGGAGTGCGATCTTCCTGAG
GCCGATACTGTCGTCGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAACGTGA
CCTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTTACTCGCTCACATT
TAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATTTTTGATGGCGTTAACTCGGCGTTT
CATCTGTGGTGCAACGGGCGCTGGGTCGGTTACGGCCAGGACAGTCGTTTGCCGTCTGAATTTGACCTGA
GCGCATTTTTACGCGCCGGAGAAAACCGCCTCGCGGTGATGGTGCTGCGCTGGAGTGACGGCAGTTATCT
GGAAGATCAGGATATGTGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACA
CAAATCAGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTCAGCCGCGCTGTACTGGAGGCTGAAG
TTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAGGGTGAAACGCAGGT
CGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGTGGTGGTTATGCCGATCGCGTCACA
CTACGTCTGAACGTCGAAAACCCGAAACTGTGGAGCGCCGAAATCCCGAATCTCTATCGTGCGGTGGTTG
AACTGCACACCGCCGACGGCACGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTGCGGAT
TGAAAATGGTCTGCTGCTGCTGAACGGCAAGCCGTTGCTGATTCGAGGCGTTAACCGTCACGAGCATCAT
CCTCTGCATGGTCAGGTCATGGATGAGCAGACGATGGTGCAGGATATCCTGCTGATGAAGCAGAACAACT
TTAACGCCGTGCGCTGTTCGCATTATCCGAACCATCCGCTGTGGTACACGCTGTGCGACCGCTACGGCCT
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GTATGTGGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCG
CGCTGGCTACCGGCGATGAGCGAACGCGTAACGCGAATGGTGCAGCGCGATCGTAATCACCCGAGTGTGA
TCATCTGGTCGCTGGGGAATGAATCAGGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATC
TGTCGATCCTTCCCGCCCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATATTATTTGC
CCGATGTACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAAAATGGC
TTTCGCTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCACGCGATGGGTAACAGTCTTGG
CGGTTTCGCTAAATACTGGCAGGCGTTTCGTCAGTATCCCCGTTTACAGGGCGGCTTCGTCTGGGACTGG
GTGGATCAGTCGCTGATTAAATATGATGAAAACGGCAACCCGTGGTCGGCTTACGGCGGTGATTTTGGCG
ATACGCCGAACGATCGCCAGTTCTGTATGAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCAGCGCT
GACGGAAGCAAAACACCAGCAGCAGTTTTTCCAGTTCCGTTTATCCGGGCAAACCATCGAAGTGACCAGC
GAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGATGGTAAGCCGCTGG
CAAGCGGTGAAGTGCCTCTGGATGTCGCTCCACAAGGTAAACAGTTGATTGAACTGCCTGAACTACCGCA
GCCGGAGAGCGCCGGGCAACTCTGGCTCACAGTACGCGTAGTGCAACCGAACGCGACCGCATGGTCAGAA
GCCGGGCACATCAGCGCCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGACGCTCCCCGCCGCGT
CCCACGCCATCCCGCATCTGACCACCAGCGAAATGGATTTTTGCATCGAGCTGGGTAATAAGCGTTGGCA
ATTTAACCGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAACTGCTGACGCCGCTG
CGCGATCAGTTCACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGACCCTA
ACGCCTGGGTCGAACGCTGGAAGGCGGCGGGCCATTACCAGGCCGAAGCAGCGTTGTTGCAGTGCACGGC
AGATACACTTGCTGATGCGGTGCTGATTACGACCGCTCACGCGTGGCAGCATCAGGGGAAAACCTTATTT
ATCAGCCGGAAAACCTACCGGATTGATGGTAGTGGTCAAATGGCGATTACCGTTGATGTTGAAGTGGCGA
GCGATACACCGCATCCGGCGCGGATTGGCCTGAACTGCCAGCTGGCGCAGGTAGCAGAGCGGGTAAACTG
GCTCGGATTAGGGCCGCAAGAAAACTATCCCGACCGCCTTACTGCCGCCTGTTTTGACCGCTGGGATCTG
CCATTGTCAGACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACGCGCGAAT
TGAATTATGGCCCACACCAGTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTACAGTCAACAGCAACT
GATGGAAACCAGCCATCGCCATCTGCTGCACGCGGAAGAAGGCACATGGCTGAATATCGACGGTTTCCAT
ATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCAGTATCGGCGGAATTCCAGCTGAGCGCCGGTCGCT
ACCATTACCAGTTGGTCTGGTGTCAAAAATAAtaataaccgggcaggccatgtctgccgtcgacaccaag
cttccactgcagccagagctcggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgct
gctggttcgctcataagtaaaaaacggcacctggtgccgtttttttgtctgaaacaagctgagcaataac
tagcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggaggaactatatccgg
attggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtga
ccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgc
cggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctc
gaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgcc
ctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctat
ctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatt
taacaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaa
tgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaattaattc
TTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTT
TGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGT
ATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTT
ATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTC
CAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCA
TTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGA
ATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAAT
ACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAAT
GCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATT
GGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATT
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GTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAAT
TTAATCGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATGGCTCATaacaccccttgtattactgtttat
gtaagcagacagttttattgttcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcaga
ccccgtagaaaagatcaaaggatcttcTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACA
AAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAA
CTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGAT
AAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGG
GGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCT
ATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACA
GGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACC
TCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAaacgccagcaacgc
ggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgat
tctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgca
gcgagtcagtgagcgaggaagcggaagagcgcctgatgcggtattttctccttacgcatctgtgcggtat
ttcacaccgcaatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatacactcc
gctatcgctacgtgactgggtcatggctgcgccccgacacccgccaacacccgctgacgcgccctgacgg
gcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggt
tttcaccgtcatcaccgaaacgcgcgaggcagctgcggtaaagctcatcagcgtggtcgtgaagcgattc
acagatgtctgcctgttcatccgcgtccagctcgttgagtttctccagaagcgttaatgtctggcttctg
ataaagcgggccatgttaagggcggttttttcctgtttggtcactgatgcctccgtgtaagggggatttc
tgttcatgggggtaatgataccgatgaaacgagagaggatgctcacgatacgggttactgatgatgaaca
tgcccggttactggaacgttgtgagggtaaacaactggcggtatggatgcggcgggaccagagaaaaatc
actcagggtcaatgccagcgcttcgttaatacagatgtaggtgttccacagggtagccagcagcatcctg
cgatgcagatccg

pJG780
gaattcccactcgagcatcgtcggcatcggcatggcgaaTTAATCTTTCTGCGAATTGAGATGACGCCAC
TGGCTGGGCGTCATCCCGGTTTCCCGGGTAAACACCACCGAAAAATAGTTACTATCTTCAAAGCCACATT
CGGTCGAAATATCACTGATTAACAGGCGGCTATGCTGGAGAAGATATTGCGCATGACACACTCTGACCTG
TCGCAGATATTGATTGATGGTCATTCCAGTCTGCTGGCGAAATTGCTGACGCAAAACGCGCTCACTGCAC
GATGCCTCATCACAAAATTTATCCAGCGCAAAGGGACTTTTCAGGCTAGCCGCCAGCCGGGTAATCAGCT
TATCCAGCAACGTTTCGCTGGATGTTGGCGGCAACGAATCACTGGTGTAACGATGGCGATTCAGCAACAT
CACCAACTGCCCGAACAGCAACTCAGCCATTTCGTTAGCAAACGGCACATGCTGACTACTTTCATGCTCA
AGCTGACCGATAACCTGCCGCGCCTGCGCCATCCCCATGCTACCTAAGCGCCAGTGTGGTTGCCCTGCGC
TGGCGTTAAATCCCGGAATCGCCCCCTGCCAGTCAAGATTCAGCTTCAGACGCTCCGGGCAATAAATAAT
ATTCTGCAAAACCAGATCGTTAACGGAAGCGTAGGAGTGTTTATCGTCAGCATGAATGTAAAAGAGATCG
CCACGGGTAATGCGATAAGGGCGATCGTTGAGTACATGCAGGCCATTACCGCGCCAGACAATCACCAGCT
CACAAAAATCATGTGTATGTTCAGCAAAGACATCTTGCGGATAACGGTCAGCCACAGCGACTGCCTGCTG
GTCGCTGGCAAAAAAATCATCTTTGAGAAGTTTTAACTGATGCGCCACcgtggctacctcggccagagaa
cgaagttgattattcgcaatatggcgtacaaatacgttgagaagattcgcgTTATTGCAGAAAGCCATCC
CGTCCCTGGCGAATATCACGCGGTGACCAGTTAAACTCTCGGCGAAAAAGCGTCGAAAAGTGGTTACTGT
CGCTGAATCCACAGCGATAGGCGATGTCAGTAACGCTGGCCTCGCTGTGGCGTAGCAGATGTCGGGCTTT
CATCAGTCGCAGGCGGTTCAGGTATCGCTGAGGCGTCAGTCCCGTTTGCTGCTTAAGCTGCCGATGTAGC
GTACGCAGTGAAAGAGAAAATTGATCCGCCACGGCATCCCAATTCACCTCATCGGCAAAATGGTCCTCCA
GCCAGGCCAGAAGCAAGTTGAGACGTGATGCGCTGTTTTCCAGGTTCTCCTGCAAACTGCTTTTACGCAG
CAAGAGCAGTAATTGCATAAACAAGATCTCGCGACTGGCGGTCGAGGGTAAATCATTTTCCCCTTCCTGC
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TGTTCCATCTGTGCAACCAGCTGTCGCACCTGCTGCAATACGCTGTGGTTAACGCGCCAGTGAGACGGAT
ACTGCCCATCCAGCTCTTGTGGCAGCAACTGATTCAGCCCGGCGAGAAACTGAAATCGATCCGGCGAGCG
ATACAGCACATTGGTCAGACACAGATTATCGGTATGTTCATACAGATGCCGATCATGATCGCGTACGAAA
CAGACCGTGCCACCGGTGATGGTATAGGGCTGCCCATTAAACACATGAATACCCGTGCCATGTTCGACAA
TCACAATTTCATGAAAATCATGATGATGTTCAGGAAAATCCGCCTGCGGGAGCCGGGGTTCTATCGCCAC
GGACGCGTTACCAGACGGAAAAAAATCCACACTATGTAATACGGTCATactggcctcctgatgtcgtcaa
cacggcgaaatagtaatcacgaggtcaggttcttaccttaaattttcgacggaaaaccacgtaaaaaacg
tcgatttttcaagatacagcgtgaattttcaggaaatgcggtgagcatcacatCACCACAATTCAGCAAA
TTGTGAACATCATCACGTTCATCTTTCCCTGGTTGCCAATGGCCCATTTTCCTGTCAGTAACGAGAAGGT
CGCGAATTCAGGCGCTTTTTAGACTGGTCGTAatgaaattcagcGGTACCaccGTCGACaccAAGCTTcc
aCTGCAGccaGAGCTCggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgctgg
ttcgctcataagtaaaaaacggcacctggtgccgtttttttgtctgaaacaagctgagcaataactagca
taaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggaggaactatatccggattgg
cgaatgggacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgct
acacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggct
ttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccc
caaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttg
acgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcgg
tctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaaca
aaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgc
gcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaattaattcTTAGA
AAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAA
AAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGG
TCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAA
GTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCAGAC
TTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGT
GATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCA
ACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTG
GAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTG
ATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAA
CGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGC
ACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAAT
CGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATGGCTCATaacaccccttgtattactgtttatgtaag
cagacagttttattgttcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccg
tagaaaagatcaaaggatcttcTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAA
ACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGC
TTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACT
CTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTC
GTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGT
TCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAG
AAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGA
GCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGA
CTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAaacgccagcaacgcggcct
ttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgt
ggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgag
tcagtgagcgaggaagcggaagagcgcctgatgcggtattttctccttacgcatctgtgcggtatttcac
accgcaatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatacactccgctat
cgctacgtgactgggtcatggctgcgccccgacacccgccaacacccgctgacgcgccctgacgggcttg
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tctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttca
ccgtcatcaccgaaacgcgcgaggcagctgcggtaaagctcatcagcgtggtcgtgaagcgattcacaga
tgtctgcctgttcatccgcgtccagctcgttgagtttctccagaagcgttaatgtctggcttctgataaa
gcgggccatgttaagggcggttttttcctgtttggtcactgatgcctccgtgtaagggggatttctgttc
atgggggtaatgataccgatgaaacgagagaggatgctcacgatacgggttactgatgatgaacatgccc
ggttactggaacgttgtgagggtaaacaactggcggtatggatgcggcgggaccagagaaaaatcactca
gggtcaatgccagcgcttcgttaatacagatgtaggtgttccacagggtagccagcagcatcctgcgatg
cagatccg

pJG795
gaattcccactcgagacgtcTTAAGACCCACTTTCACATTTAAGTTGTTTTTCTAATCCGCATATGATCA
ATTCAAGGCCGAATAAGAAGGCTGGCTCTGCACCTTGGTGATCAAATAATTCGATAGCTTGTCGTAATAA
TGGCGGCATACTATCAGTAGTAGGTGTTTCCCTTTCTTCTTTAGCGACTTGATGCTCTTGATCTTCCAAT
ACGCAACCTAAAGTAAAATGCCCCACAGCGCTGAGTGCATATAATGCATTCTCTAGTGAAAAACCTTGTT
GGCATAAAAAGGCTAATTGATTTTCGAGAGTTTCATACTGTTTTTCTGTAGGCCGTGTACCTAAATGTAC
TTTTGCTCCATCGCGATGACTTAGTAAAGCACATCTAAAACTTTTAGCGTTATTACGTAAAAAATCTTGC
CAGCTTTCCCCTTCTAAAGGGCAAAAGTGAGTATGGTGCCTATCTAACATCTCAATGGCTAAGGCGTCGA
GCAAAGCCCGCTTATTTTTTACATGCCAATACAATGTAGGCTGCTCTACACCTAGCTTCTGGGCGAGTTT
ACGGGTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCTGTTAATCACTTTACTTTTA
TCTAATCTAGACATcattaattcctaatttttGTTGACACTCTATCGTTGATAGAGTTATTTTACCACTC
CCTATCAGTGATAGAGAAaaGGTACCgcgTCTAGAcccGTCGACgccAAGCTTccgCTGCAGcccGAGCT
Cgcttcctggtgtccctgttgataccgggaagccctgggccaacttttggcgaaaatgagacgttgatcg
gcacgtaagaggttccaactttcaccataatgaaataagatcactaccgggcgtattttttgagttatcg
agattttcaggagctaaggaagctaaaATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCC
AATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCA
GCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCAC
ATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATAT
GGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGA
ATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTG
GCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCA
GTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATAC
GCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTCTGTGATGGCTTCCATGTC
GGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAAtttttttaaggca
gttattggtgcccttaaacgcctggtgtaaaaacccgcttcggcgggtttttttatgctgattaagcatt
ggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaag
gatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactga
gcgtcagaccccttaataagatgatcttcTTGAGATCGTTTTGGTCTGCGCGTAATCTCTTGCTCTGAAA
ACGAAAAAACCGCCTTGCAGGGCGGTTTTTCGAAGGTTCTCTGAGCTACCAACTCTTTGAACCGAGGTAA
CTGGCTTGGAGGAGCGCAGTCACCAAAACTTGTCCTTTCAGTTTAGCCTTAACCGGCGCATGACTTCAAG
ACTAACTCCTCTAAATCAATTACCAGTGGCTGCTGCCAGTGGTGCTTTTGCATGTCTTTCCGGGTTGGAC
TCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGACTGAACGGGGGGTTCGTGCATACAGTCCAGCT
TGGAGCGAACTGCCTACCCGGAACTGAGTGTCAGGCGTGGAATGAGACAAACGCGGCCATAACAGCGGAA
TGACACCGGTAAACCGAAAGGCAGGAACAGGAGAGCGCACGAGGGAGCCGCCAGGGGGAAACGCCTGGTA
TCTTTATAGTCCTGTCGGGTTTCGCCACCACTGATTTGAGCGTCAGATTTCGTGATGCTTGTCAGGGGGG
CGGAGCCTATGGAAAaacggctttgccgcggccctctcacttccctgttaagtatcttcctggcatcttc
caggaaatctccgccccgttcgtaagccatttccgctcgccgcagtcgaacgaccgagcgtagcgagtca
gtgagcgaggaagcggaatatatcctgtatcacatattctgctgacgcaccggtgcagccttttttctcc
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tgccacatgaagcacttcactgacaccctcatcagtgccaacatagtaagccagtatacactccgctagc
gctgaggtcagcttgcccacgtagacc

pJG745
GAATTCccaCTCGAGccaGGTACCaccTCTAGAcccGTCGACgccAAGCTTccgCTGCAGcccGAGCTCg
cttcctggtgtccctgttgataccgggaagccctgggccaacttttggcgaaaatgagacgttgatcggc
acgtaagaggttccaactttcaccataatgaaataagatcactaccgggcgtattttttgagttatcgag
attttcaggagctaaggaagctaaaATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAA
TGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGC
TGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACAT
TCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGG
GATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAAT
ACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGC
CTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGT
TTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGC
AAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTCTGTGATGGCTTCCATGTCGG
CAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAAtttttttaaggcagt
tattggtgcccttaaacgcctggtgtaaaaacccgcttcggcgggtttttttatgctgattaagcattgg
taactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaagga
tctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagc
gtcagaccccttaataagatgatcttcTTGAGATCGTTTTGGTCTGCGCGTAATCTCTTGCTCTGAAAAC
GAAAAAACCGCCTTGCAGGGCGGTTTTTCGAAGGTTCTCTGAGCTACCAACTCTTTGAACCGAGGTAACT
GGCTTGGAGGAGCGCAGTCACCAAAACTTGTCCTTTCAGTTTAGCCTTAACCGGCGCATGACTTCAAGAC
TAACTCCTCTAAATCAATTACCAGTGGCTGCTGCCAGTGGTGCTTTTGCATGTCTTTCCGGGTTGGACTC
AAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGACTGAACGGGGGGTTCGTGCATACAGTCCAGCTTG
GAGCGAACTGCCTACCCGGAACTGAGTGTCAGGCGTGGAATGAGACAAACGCGGCCATAACAGCGGAATG
ACACCGGTAAACCGAAAGGCAGGAACAGGAGAGCGCACGAGGGAGCCGCCAGGGGGAAACGCCTGGTATC
TTTATAGTCCTGTCGGGTTTCGCCACCACTGATTTGAGCGTCAGATTTCGTGATGCTTGTCAGGGGGGCG
GAGCCTATGGAAAaacggctttgccgcggccctctcacttccctgttaagtatcttcctggcatcttcca
ggaaatctccgccccgttcgtaagccatttccgctcgccgcagtcgaacgaccgagcgtagcgagtcagt
gagcgaggaagcggaatatatcctgtatcacatattctgctgacgcaccggtgcagccttttttctcctg
ccacatgaagcacttcactgacaccctcatcagtgccaacatagtaagccagtatacactccgctagcgc
tgaggtcagcttgcccacgtagacc

Inserts
PlacT5 (LacIq)(XhoI/SalI)
CTCGAGccggtgcctaatgagtgagctaacttacattaattgcgttgcgcTCActgcccgctttccagtc
gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattggg
cgccagggtggtttttcttttcaccagtgagacgggcaacagctgattgcccttcaccgcctggccctga
gagagttgcagcaagcggtccacgctggtttgccccagcaggcgaaaatcctgtttgatggtggttaacg
gcgggatataacatgagctgtcttcggtatcgtcgtatcccactaccgagatgtccgcaccaacgcgcag
cccggactcggtaatggcgcgcattgcgcccagcgccatctgatcgttggcaaccagcatcgcagtggga
acgatgccctcattcagcatttgcatggtttgttgaaaaccggacatggcactccagtcgccttcccgtt
ccgctatcggctgaatttgattgcgagtgagatatttatgccagccagccagacgcagacgcgccgagac
agaacttaatgggcccgctaacagcgcgatttgctggtgacccaatgcgaccagatgctccacgcccagt
cgcgtaccgtcttcatgggagaaaataatactgttgatgggtgtctggtcagagacatcaagaaataacg
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ccggaacattagtgcaggcagcttccacagcaatggcatcctggtcatccagcggatagttaatgatcag
cccactgacgcgttgcgcgagaagattgtgcaccgccgctttacaggcttcgacgccgcttcgttctacc
atcgacaccaccacgctggcacccagttgatcggcgcgagatttaatcgccgcgacaatttgcgacggcg
cgtgcagggccagactggaggtggcaacgccaatcagcaacgactgtttgcccgccagttgttgtgccac
gcggttgggaatgtaattcagctccgccatcgccgcttccactttttcccgcgttttcgcagaaacgtgg
ctggcctggttcaccacgcgggaaacggtctgataagagacaccggcatactctgcgacatcgtataacg
ttactggtttCACattcaccaccctgaattgactctcttccgggcgctATCATGccataccgcgaaaggt
tTTGCACcattcgatggtgtccgggaTCC

PlacT5 (LacIWT) (XhoI/SalI)
CTCGAGccggtgcctaatgagtgagctaacttacattaattgcgttgcgcTCActgcccgctttccagtc
gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattggg
cgccagggtggtttttcttttcaccagtgagacgggcaacagctgattgcccttcaccgcctggccctga
gagagttgcagcaagcggtccacgctggtttgccccagcaggcgaaaatcctgtttgatggtggttaacg
gcgggatataacatgagctgtcttcggtatcgtcgtatcccactaccgagatgtccgcaccaacgcgcag
cccggactcggtaatggcgcgcattgcgcccagcgccatctgatcgttggcaaccagcatcgcagtggga
acgatgccctcattcagcatttgcatggtttgttgaaaaccggacatggcactccagtcgccttcccgtt
ccgctatcggctgaatttgattgcgagtgagatatttatgccagccagccagacgcagacgcgccgagac
agaacttaatgggcccgctaacagcgcgatttgctggtgacccaatgcgaccagatgctccacgcccagt
cgcgtaccgtcttcatgggagaaaataatactgttgatgggtgtctggtcagagacatcaagaaataacg
ccggaacattagtgcaggcagcttccacagcaatggcatcctggtcatccagcggatagttaatgatcag
cccactgacgcgttgcgcgagaagattgtgcaccgccgctttacaggcttcgacgccgcttcgttctacc
atcgacaccaccacgctggcacccagttgatcggcgcgagatttaatcgccgcgacaatttgcgacggcg
cgtgcagggccagactggaggtggcaacgccaatcagcaacgactgtttgcccgccagttgttgtgccac
gcggttgggaatgtaattcagctccgccatcgccgcttccactttttcccgcgttttcgcagaaacgtgg
ctggcctggttcaccacgcgggaaacggtctgataagagacaccggcatactctgcgacatcgtataacg
ttactggtttCACattcaccaccctgaattgactctcttccgggcgctATCATGccataccgcgaaaggt
tTTGCGCcattcgatggtgtccgggaTCC

Ptet (XhoI/SalI)
ctcgagACGTCTTAAGACCCACTTTCACATTTAAGTTGTTTTTCTAATCCGCATATGATCAATTCAAGGC
CGAATAAGAAGGCTGGCTCTGCACCTTGGTGATCAAATAATTCGATAGCTTGTCGTAATAATGGCGGCAT
ACTATCAGTAGTAGGTGTTTCCCTTTCTTCTTTAGCGACTTGATGCTCTTGATCTTCCAATACGCAACCT
AAAGTAAAATGCCCCACAGCGCTGAGTGCATATAATGCATTCTCTAGTGAAAAACCTTGTTGGCATAAAA
AGGCTAATTGATTTTCGAGAGTTTCATACTGTTTTTCTGTAGGCCGTGTACCTAAATGTACTTTTGCTCC
ATCGCGATGACTTAGTAAAGCACATCTAAAACTTTTAGCGTTATTACGTAAAAAATCTTGCCAGCTTTCC
CCTTCTAAAGGGCAAAAGTGAGTATGGTGCCTATCTAACATCTCAATGGCTAAGGCGTCGAGCAAAGCCC
GCTTATTTTTTACATGCCAATACAATGTAGGCTGCTCTACACCTAGCTTCTGGGCGAGTTTACGGGTTGT
TAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCTGTTAATCACTTTACTTTTATCTAATCTA
GACATCATTAATTCCTAATTTTTGTTGACACTCTATCGTTGATAGAGTTATTTTACCACTCCCTATCAGT
GATAGAGAAAAggtacc

PrhaBAD (XhoI/SalI)
ctcgagCATCGTCGGCATCGGCATGGCGAAttaATCTTTCTGCGAATTGAGATGACGCCACTGGCTGGGC
GTCATCCCGGTTTCCCGGGTAAACACCACCGAAAAATAGTTACTATCTTCAAAGCCACATTCGGTCGAAA
TATCACTGATTAACAGGCGGCTATGCTGGAGAAGATATTGCGCATGACACACTCTGACCTGTCGCAGATA
TTGATTGATGGTCATTCCAGTCTGCTGGCGAAATTGCTGACGCAAAACGCGCTCACTGCACGATGCCTCA
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TCACAAAATTTATCCAGCGCAAAGGGACTTTTCAGGCTAGCCGCCAGCCGGGTAATCAGCTTATCCAGCA
ACGTTTCGCTGGATGTTGGCGGCAACGAATCACTGGTGTAACGATGGCGATTCAGCAACATCACCAACTG
CCCGAACAGCAACTCAGCCATTTCGTTAGCAAACGGCACATGCTGACTACTTTCATGCTCAAGCTGACCG
ATAACCTGCCGCGCCTGCGCCATCCCCATGCTACCTAAGCGCCAGTGTGGTTGCCCTGCGCTGGCGTTAA
ATCCCGGAATCGCCCCCTGCCAGTCAAGATTCAGCTTCAGACGCTCCGGGCAATAAATAATATTCTGCAA
AACCAGATCGTTAACGGAAGCGTAGGAGTGTTTATCGTCAGCATGAATGTAAAAGAGATCGCCACGGGTA
ATGCGATAAGGGCGATCGTTGAGTACATGCAGGCCATTACCGCGCCAGACAATCACCAGCTCACAAAAAT
CATGTGTATGTTCAGCAAAGACATCTTGCGGATAACGGTCAGCCACAGCGACTGCCTGCTGGTCGCTGGC
AAAAAAATCATCTTTGAGAAGTTTTAACTGATGCGCcacCGTGGCTACCTCGGCCAGAGAACGAAGTTGA
TTATTCGCAATATGGCGTACAAATACGTTGAGAAGATTCGCGttaTTGCAGAAAGCCATCCCGTCCCTGG
CGAATATCACGCGGTGACCAGTTAAACTCTCGGCGAAAAAGCGTCGAAAAGTGGTTACTGTCGCTGAATC
CACAGCGATAGGCGATGTCAGTAACGCTGGCCTCGCTGTGGCGTAGCAGATGTCGGGCTTTCATCAGTCG
CAGGCGGTTCAGGTATCGCTGAGGCGTCAGTCCCGTTTGCTGCTTAAGCTGCCGATGTAGCGTACGCAGT
GAAAGAGAAAATTGATCCGCCACGGCATCCCAATTCACCTCATCGGCAAAATGGTCCTCCAGCCAGGCCA
GAAGCAAGTTGAGACGTGATGCGCTGTTTTCCAGGTTCTCCTGCAAACTGCTTTTACGCAGCAAGAGCAG
TAATTGCATAAACAAGATCTCGCGACTGGCGGTCGAGGGTAAATCATTTTCCCCTTCCTGCTGTTCCATC
TGTGCAACCAGCTGTCGCACCTGCTGCAATACGCTGTGGTTAACGCGCCAGTGAGACGGATACTGCCCAT
CCAGCTCTTGTGGCAGCAACTGATTCAGCCCGGCGAGAAACTGAAATCGATCCGGCGAGCGATACAGCAC
ATTGGTCAGACACAGATTATCGGTATGTTCATACAGATGCCGATCATGATCGCGTACGAAACAGACCGTG
CCACCGGTGATGGTATAGGGCTGCCCATTAAACACATGAATACCCGTGCCATGTTCGACAATCACAATTT
CATGAAAATCATGATGATGTTCAGGAAAATCCGCCTGCGGGAGCCGGGGTTCTATCGCCACGGACGCGTT
ACCAGACGGAAAAAAATCCACACTATGTAATACGGTcatACTGGCCTCCTGATGTCGTCAACACGGCGAA
ATAGTAATCACGAGGTCAGGTTCTTACCTTAAATTTTCGACGGAAAACCACGTAAAAAACGTCGATTTTT
CAAGATACAGCGTGAATTTTCAGGAAATGCGGTGAGCATCACATCACCACAATTCAGCAAATTGTGAACA
TCATCACGTTCATCTTTCCCTGGTTGCCAATGGCCCATTTTCCTGTCAGTAACGAGAAGGTCGCGAATTC
AGGCGCTTTTTAGACTGGTCGTaATGAAATTCAGCggtacc

ParaBAD (XhoI/KpnI)
ctcgagGCTACTCCGTCAAGCCGTCAATTGTCTGATTCGTTACCAAttaTGACAACTTGACGGCTACATC
ATTCACTTTTTCTTCACAACCGGCACGAAACTCGCTCGGGCTGGCCCCGGTGCATTTTTTAAATACTCGC
GAGAAATAGAGTTGATCGTCAAAACCAACATTGCGACCGACGGTGGCGATAGGCATCCGGGTAGTGCTCA
AAAGCAGCTTCGCCTGACTAATGCGTTGGTCCTCGCGCCAGCTTAAGACGCTAATCCCTAACTGCTGGCG
GAAAAGATGTGACAGACGCGACGGCGACAAGCAAACATGCTGTGCGACGCTGGCGATATCAAAATTGCTG
TCTGCCAGGTGATCGCTGATGTACTGACAAGCCTCGCGTACCCGATTATCCATCGGTGGATGGAGCGACT
CGTTAATCGCTTCCATGCGCCGCAGTAACAATTGCTCAAGCAGATTTATCGCCAGCAGCTCCGAATAGCG
CCCTTCCCCTTGCCCGGCGTTAATGATTTGCCCAAACAGGTCGCTGAAATGCGGCTGGTGCGCTTCATCC
GGGCGAAAGAAACCCGTATTGGCAAATATTGACGGCCAGTTAAGCCATTCATGCCAGTAGGCGCGCGGAC
GAAAGTAAACCCACTGGTGATACCATTCGCGAGCCTCCGGATGACGACCGTAGTGATGAATCTCTCCTGG
CGGGAACAGCAAAATATCACCCGGTCGGCAGACAAATTCTCGTCCCTGATTTTTCACCACCCCCTGACCG
CGAATGGTGAGATTGAGAATATAACCTTTCATTCCCAGCGGTCGGTCGATAAAAAAATCGAGATAACCGT
TGGCCTCAATCGGCGTTAAACCCGCCACCAGATGGGCGTTAAACGAGTATCCCGGCAGCAGGGGATCATT
TTGCGCTTCAGCcatACTTTTCATACTCCCACCATTCAGAGAAGAAACCAATTGTCCATATTGCATCAGA
CATTGCCGTCACTGCGTCTTTTACTGGCTCTTCTCGCTAACCCAACCGGTAACCCCGCTTATTAAAAGCA
TTCTGTAACAAAGCGGGACCAAAGCCATGACAAAAACGCGTAACAAAAGTGTCTATAATCACGGCAGAAA
AGTCCACATTGATTATTTGCACGGCGTCACACTTTGCTATGCCATAGCATTTTTATCCATAAGATTAGCG
GATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCATaCCCGTTTTTggtacc
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msfGFP (KpnI/SalI)
ggtaccGGAGGTCACATATGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCT
GGACGGCGACGTAAACGGCCACAAGTTCAGCGTGCGCGGCGAGGGCGAGGGCGATGCCACCAACGGCAAG
CTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGA
CCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCAT
GCCCGAAGGCTACGTCCAGGAGCGCACCATCTCCTTCAAGGACGACGGCACCTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCA
ACATCCTGGGGCACAAGCTGGAGTACAACTTCAACAGCCACAACGTCTATATCACGGCCGACAAGCAGAA
GAACGGCATCAAGGCGAACTTCAAGATCCGCCACAACGTCGAGGACGGCAGCGTGCAGCTCGCCGACCAC
TACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGT
CCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGG
GATCACTCTCGGCATGGACGAGCTGTACAAGTAAgtcgac

McjB & McjC (KpnI/SalI)
ggtaccTACAGGAGGGAGTGTGCAAAATGATCCGTTACTGCTTAACCAGTTATAGAGAGGATCTTGTTAT
CCTGGATATAATTAATGATAGTTTCAGCATAGTGCCTGACGCAGGTAGCTTGCTAAAAGAAAGAGATAAA
TTGCTTAAAGAATTCCCACAACTATCTTACTTTTTTGACAGTGAATATCATATTGGAAGTGTTTCTCGTA
ATAGTGACACTTCTTTTCTTGAAGAACGCTGGTTTCTACCAGAACCTGACAAAACATTATATAAGTGTTC
TCTATTTAAACGATTTATATTATTACTCAAAGTCTTTTACTATAGCTGGAATATTGAAAAAAAAGGGATG
GCATGGATTTTCATAAGTAATAAAAAAGAGAATAGGCTATACTCCTTGAATGAAGAGCATCTTATCCGGA
AAGAAATTAGTAATCTTTCCATTATCTTTCATCTTAATATTTTTAAATCTGACTGTCTTACCTATTCATA
CGCACTAAAAAGAATTCTTAATTCCAGAAATATTGATGCTCATCTTGTTATTGGTGTAAGGACACAACCT
TTTTATAGCCACTCTTGGGTGGAGGTTGGGGGACAAGTTATCAATGATGCTCCCAATATGCGGGATAAAT
TATCTGTTATTGCAGAGATATAGTTATGGAAATATTTAATGTCAAGTTAAATGATACTTCAATTAGAATT
ATTTTCTGTAAAACGCTTTCTGCCTTCCGGACAGAAAATACCATCGTTATGCTCAAAGGAAAAGCAGTTT
CAAATGGCAAACCTGTATCCACAGAGGAGATTGCCAGAGTAGTGGAAGAAAAAGGTGTTTCAGAAGTAAT
AGAAAATTTAGATGGTGTTTTCTGTATCCTAATTTATCATTTTAATGATCTCCTTATAGGGAAAAGCATT
CAATCAGGCCCCGCTCTATTTTATTGTAAAAAGAATATGGATATTTTTGTTTCGGATAAAATTTCTGATA
TCAAATTTTTGAATCCAGATATGACATTCAGTCTAAATATAACAATGGCAGAACATTATCTGTCAGGAAA
TCGAATAGCAACCCAGGAATCACTAATCACTGGCATTTACAAAGTAAATAATGGTGAGTTTATAAAATTT
AATAATCAGTTGAAACCTGTGCTACTTCGTGATGAGTTTAGTATTACCAAAAAGAACAATTCAACTATCG
ACAGTATCATTGATAATATTGAGATGATGCGGGATAATAGAAAAATAGCCCTATTATTTTCCGGAGGATT
GGATTCTGCATTAATTTTTCACACACTTAAAGAATCAGGTAACAAATTCTGCGCTTATCATTTTTTTTCT
GATGAATCTGATGACAGTGAAAAGTATTTTGCTAAGGAATACTGTTCAAAATATGGAGTTGATTTTATAT
CTGTTAATAAAAACATCAACTTTAATGAAAAACTTTATTTCAATTTAAATCCTAATAGTCCGGACGAAAT
CCCTTTGATATTTGAACAGACAGATGAAGAAGGTGAAGGTCAGCCCCCCATAGACGATGATTTATTATAT
CTATGTGGTCACGGTGGAGATCATATTTTCGGACAAAATCCTTCAGAACTTTTTGGCATTGATGCATATC
GAAGTCATGGCTTGATGTTTATGCATAAAAAAATAGTAGAATTTTCCAATCTCAAGGGAAAGAGATATAA
AGATATCATATTTTCAAATATTTCCGCATTCATTAATACATCCAACGGATGTTCTCCAGCAAAGCAAGAG
CACGTATCAGATATGAAACTTGCCTCTGCTCAGTTTTTTGCAACTGATTATACAGGAAAAATTAATAAAC
TAACTCCATTCCTGCATAAAAATATTATCCAGCATTATGCTGGCTTACCAGTTTTTAGTCTATTTAACCA
GCACTTTGATCGTTATCCCGTTCGTTATGAAGCGTTTCAACGATTTGGTTCAGATATTTTCTGGAAAAAA
ACCAAACGGTCATCTTCACAGCTAATATTCAGAATTCTATCCGGTAAAAAGGATGAACTAGTGAATACAA
TAAAACAGTCAGGATTAATTGAAATATTAGGCATTAACCATATTGAATTGGAAAGCATTTTGTATGAAAA
TACGACTACACGTCTGACAATGGAACTACCATATATACTTAACTTATACCGTCTGGCAAAATTCATTCAA
CTTCAATCCATTGATTATAAAGGTTAAgtcgac
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McjA (KpnI/SalI)
GGTACCaaataaggaggctaaaaATGATTAAGCATTTTCATTTTAATAAACTGTCTTCTGGTAAAAAAAA
TAATGTTCCATCTCCTGCAAAGGGGGTTATACAAATAAAAAAATCAGCATCGCAACTCACAAAAGGTGGT
GCAGGACATGTGCCTGAGTATTTTGTGGGGATTGGTACACCTATATCTTTCTATGGCTGAgtcgac

McjA with BamHI modification (KpnI/SalI)
GGTACCaaataaggaggctaaaaATGATTAAGCATTTTCATTTTAATAAACTGTCTTCTGGTAAAAAAAA
TAATGTTCCATCTCCTGCAAAGGGGGTTATACAAATAAAAAAATCAGCATCGCAACTCACAAAAGGTGGA
TCCGGACATGTGCCTGAGTATTTTGTGGGGATTGGTACACCTATATCTTTCTATGGCTGAgtcgac

Supplementary Table 2. Plasmid Table
Plasmid Name
pJG756
pJG753
pJG808
pJG751
pJG749
pJG804
pJG783
pJG805
pJG809
pJG810
pJG798
pJG803
pJG797

Parent Plasmid
pJG747
pJG747
pJG747
pJG747
pJG747
pJG744
pJG744
pJG744
pJG744
pJG744
pJG780
pJG780
pJG795

Insert
PlacT5(lacIq)
PlacT5(LacIWT)
Ptet
PrhaBAD
ParaBAD
Ptet, msfGFP
PrhaBAD, msfGFP
PlacT5(lacIQ), msfGFP
ParaBAD, msfGFP
PlacT5(lacIWT), msfGFP
McjA
McjA with BamHI
McjB & McjC

Supplementary Table 3. Strain Table
Strain name
C893
C894
C895
C896
C897
C901
C902

Background
DH5α
DH5α
DH5α
MDS™42 Meta ΔrecA
MDS™42 Meta ΔrecA
MDS™42 Meta ΔrecA
MDS™42 Meta ΔrecA
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Plasmid (s)
pJG797, pJG798
pJG795, pJG798
pJG797, pJG745
pJG797, pJG798
pJG795, pJG780
pJG797, pJG803
pJG795, pJG780

CHAPTER 3: Vector sequences
Parent vectors
Plasmid Features :
LacI ORF
Lac/T5 promoter
Multiple cloning site
T7 terminator
AmpR ORF
KanR ORF
CmR ORF
pCDF ori
ColE1 ori
pJG743
tggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgacc
gctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg
gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcga
ccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccct
ttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatct
cggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgattta
acaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatg
tgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaattaattcTT
AGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTG
AAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTAT
CGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTAT
CAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCA
GACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATT
CGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAAT
GCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATAC
CTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGC
TTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGG
CAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGT
CGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTT
AATCGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATGGCTCATaacaccccttgtattactgtttatgt
aagcagacagttttattgttcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagacc
ccgtagaaaagatcaaaggatcttcTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAA
AAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACT
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GGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGA
ACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAA
GTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGG
GGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTAT
GAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGG
AGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAaacgccagcaacgcgg
cctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattc
tgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagc
gagtcagtgagcgaggaagcggaagagcgcctgatgcggtattttctccttacgcatctgtgcggtattt
cacaccgcaatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatacactccgc
tatcgctacgtgactgggtcatggctgcgccccgacacccgccaacacccgctgacgcgccctgacgggc
ttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttt
tcaccgtcatcaccgaaacgcgcgaggcagctgcggtaaagctcatcagcgtggtcgtgaagcgattcac
agatgtctgcctgttcatccgcgtccagctcgttgagtttctccagaagcgttaatgtctggcttctgat
aaagcgggccatgttaagggcggttttttcctgtttggtcactgatgcctccgtgtaagggggatttctg
ttcatgggggtaatgataccgatgaaacgagagaggatgctcacgatacgggttactgatgatgaacatg
cccggttactggaacgttgtgagggtaaacaactggcggtatggatgcggcgggaccagagaaaaatcac
tcagggtcaatgccagcgcttcgttaatacagatgtaggtgttccacagggtagccagcagcatcctgcg
atgcagatccggaacataatggtgcagggcgctgacttccgcgtttccagactttacgaaacacggaaac
cgaagaccattcatgttgttgctcaggtcgcagacgttttgcagcagcagtcgcttcacgttcgctcgcg
tatcggtgattcattctgctaaccagtaaggcaaccccgccagcctagccgggtcctcaacgacaggagc
acgatcatgcgcacccgtggggccgccatgccggcgataatggcctgcttctcgccgaaacgtttggtgg
cgggaccagtgacgaaggcttgagcgagggcgtgcaagattccgaataccgcaagcgacaggccgatcat
cgtcgcgctccagcgaaagcggtcctcgccgaaaatgacccagagcgctgccggcacctgtcctacgagt
tgcatgataaagaagacagtcataagtgcggcgacgatagtcatgccccgcgcccaccggaaggagctga
ctgggttgaaggctctcaagggcatcggtcgagatcccggtgcctaatgagtgagctaacttacattaat
tgcgttgcgcTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAA
CGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAAC
AGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGCCCCAGCA
GGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGTCTTCGGTATCGTCGTATCC
CACTACCGAGATGTCCGCACCAACGCGCAGCCCGGACTCGGTAATGGCGCGCATTGCGCCCAGCGCCATC
TGATCGTTGGCAACCAGCATCGCAGTGGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAAC
CGGACATGGCACTCCAGTCGCCTTCCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATG
CCAGCCAGCCAGACGCAGACGCGCCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGA
CCCAATGCGACCAGATGCTCCACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGG
GTGTCTGGTCAGAGACATCAAGAAATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATC
CTGGTCATCCAGCGGATAGTTAATGATCAGCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCT
TTACAGGCTTCGACGCCGCTTCGTTCTACCATCGACACCACCACGCTGGCACCCAGTTGATCGGCGCGAG
ATTTAATCGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAA
CGACTGTTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCC
ACTTTTTCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGA
CACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTCACattcaccaccctgaattgactctcttc
cgggcgctatcatgccataccgcgaaaggttttgcgccattcgatggtgtccgggatctcgacgctctcc
cttatgcgactcctgcattaggaagcagcccagtagtaggttgaggccgttgagcaccgccgccgcaagg
aatggtgcatgcaaggagatggcgcccaacagtcccccggccacggggcctgccaccatacccacgccga
aacaagcgctcatgagcccgaagtggcgagcccgatcttccccatcggtgatgtcggcgatataggcgcc
agcaaccgcacctgtggcgccggtgagatctcgatcccgcgaaataaTTGTGAGCGGATAACAAttacga
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gcttcatgcacagtgaaaTCATGAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAtgtggAA
TTGTGAGCGCTCACAATTccacaacggttctaGGTACCaccTCTAGAcccGTCGACaccAAGCTTccaCT
GCAGccaGAGCTCggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgctggttc
gctcataagtaaaaaacggcacctggtgccgtttttttgtctgaaacaagctgagcaataaCTAGCATAA
CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGctgaaaggaggaactatatccggat

pED022
ctcgaggatcgatcccggtgcctaatgagtgagctaacttacattaattgcgttgcgcTCACTGCCCGCT
TTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGC
GTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTCACCGCCT
GGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGT
GGTTAACGGCGGGATATAACATGAGCTGTCTTCGGTATCGTCGTATCCCACTACCGAGATGTCCGCACCA
ACGCGCAGCCCGGACTCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCG
CAGTGGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCC
TTCCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGC
GCCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCA
CGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAG
AAATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTA
ATGATCAGCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTC
GTTCTACCATCGACACCACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGACAATTTG
CGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGCCAGTTGT
TGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACTTTTTCCCGCGTTTTCGCAG
AAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACACCGGCATACTCTGCGACATC
GTATAACGTTACTGGTTTCACattcaccaccctgaattgactctcttccgggcgctatcatgccataccg
cgaaaggttttgcgccattcgatggtgtccgggatctcgacgctctcccttatgcgactcctgcattagg
aagcagcccagtagtaggttgaggccgttgagcaccgccgccgcaaggaatggtgcatgcaaggagatgg
cgcccaacagtcccccggccacggggcctgccaccatacccacgccgaaacaagcgctcatgagcccgaa
gtggcgagcccgatcttccccatcggtgatgtcggcgatataggcgccagcaaccgcacctgtggcgccg
gtgagatctcgatcccgcgaaatAATTGTGAGCGGATAACAATTacgagcttcatgcacagtgaaaTCAT
GAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAtgtggAATTGTGAGCGCTCACAATTccac
aacggtTCTAGAaataattttgtttaactttaagaaggagatataCATATGGGATCCTGAGAGCTCggaa
atgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaata
accctgataaatgcttcaataatattgaaaaaggaagagtaTGAGTATTCAACATTTCCGTGTCGCCCTT
ATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATG
CTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAG
TTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCC
CGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACT
CACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCAT
GAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACG
ACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACT
TACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGC
TCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCA
TTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAAC
TATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAActgtcagac
caagtttactcgtaaaaacccgcttcggcgggtttttttatgctagggcggttcagtagaaaaGATCAAA
GGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTTTTGCCCTGTAAACGAAAAAACCACCTGGGGAG
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GTGGTTTGATCGAAGGTTAAGTCAGTTGGGGAACTGCTTAACCGTGGTAACTGGCTTTCGCAGAGCACAG
CAACCAAATCTGTCCTTCCAGTGTAGCCGGACTTTGGCGCACACTTCAAGAGCAACCGCGTGTTTAGCTA
AACAAATCCTCTGCGAACTCCCAGTTACCAATGGCTGCTGCCAGTGGCGTTTTACCGTGCTTTTCCGGGT
TGGACTCAAGTGAACAGTTACCGGATAAGGCGCAGCAGTCGGGCTGAACGGGGAGTTCTTGCTTACAGCC
CAGCTTGGAGCGAACGACCTACACCGAGCCGAGATACCAGTGTGTGAGCTATGAGAAAGCGCCACACTTC
CCGTAAGGGAGAAAGGCGGAACAGGTATCCGGTAAACGGCAGGGTCGGAACAGGAGAGCGCAAGAGGGAG
CGACCCGCCGGAAACGGTGGGGATCTTTAAGTCCTGTCGGGTTTCGCCCGTACTGTCAGATTCATGGTTG
AGCCTCACGGCTCCCACAGATGCACCGGAAAAGCGTCTGTTTATGTGAACTCTGGCAGGAGGGCGGAGCC
TATGGAAAAACGCCACCGGCGCGGCCCTGCTGTTTTGCCTCACATGTTAGTCCCCTGCTTATCCACGGAA
TCTGTGGGTAACTTTGTATGTGTCCGCAGCGCccgccgcagtctcacgcccggagcgtagcgaccgagtg
aa

Inserts
TclI (KpnI/XbaI) insert
ggtaccGGAGGTCACATATGTACCTGCTGTTCAAGAAAGACACCTTTTATATCAAGACCCACAACGAGGG
TATTCTGTTCAAAAACAACTTTACCAACCTGGAAGTGAAGACCCATAAAAGCTACTATGTTTTCGAGAAC
CTGATCGAATACCTGAACGGCAGCTATACCGAGAACCAGATCATCGAAAACATCAAGAACAAGAAAGTGG
CGCTGTTCTGCAAAAACATCATTAACGTTCTGAAGGAGAAAAACTTTATCTACGCGAGCGAAAACCGTCT
GGATAACCTGAGCGAGCTGGAAATCAAGATTCTGTATCTGAACAGCAAGAACATCCAACTGAGCAAAGAC
GCGTTCCTGAACAACAACAAGATCGATATTAAAACCTACAACCTGATGGAGAACGAGTTCGCGAACACCA
TGCTGAAGGAGTACTATTTTAGCCCGAGCGAAACCGCGAACATCAAGATTAGCCTGGGTAAATTTGAGAG
CGACATCGGCTACTATATCATTCCGGATGGTGAATACCTGATTGTGGGCAAAAGCAAGAAACAGCACACC
CACACCGTTAGCCTGAGCACCTATGAGATCCCGCTGCACGCGTGGCTGATCTGCCTGAACATTCTGCTGA
GCGAACTGTTCCTGTACTGCACCAGCATTTATAGCGAGGACAAGTTCGATGAAAACTACTACAAGTTCAA
CGTGCAAACCTTTGAGGGTGACTTCTTTAAGAAAGAAAACAAATAAtctaga

TclJ (XbaI/SalI) insert
tctagaGGAGGTCACATATGGAAATCTTCGAAAGCCCGGAGTTTAACATCATTCGTTACCTGAGCAACAG
CTATATTTTCAAGAGCACCAGCAAAGAACCGGACTTTCTGAACAGCATCAAAGAGCGTATTCTGCTGAAT
ACCAACGATATCATTTACAAGAAAAACATCCCGGAACGTAACATTAGCTTCCTGAGCCGTATCGAGAACA
GCATTGGTAACTTTATCTGCAACCAGATTAGCGAATACGACTACATCATCTACATCTACAACCACAAGAC
CAACAAGATCAAGAAAGTGAACTACTTCATCAGCCCGCACTACTATAAGAAACTGCCGAACGACACCACC
AACTGCTTCAACATCATTATCAACGAGCTGAAGAACAGCAAAAGCCACAACTTTCGTAGCCGTAACATTG
ATAGCATCTACAACCAGCTGGACAAATATTTCCTGGATAAGAACCTGGGTATCTGCAACATGCTGCTGGA
CAACTACGATGGCCCGTTTCCGATTAGCGTTGCGATGCTGCCGCTGGACAACGGTAAAGAGGAACCGGGT
GTGGGCCGTACCCGTAAGATCCAACGTAGCCGTGCGGTTGCGCTGCTGGAAGCGTACGAGCGTTATAGCG
GTCTGGAACCGCGTGGCAAGAAAACCATCAACCACACCGAGGATCTGAAGAGCAAGAAAGTGAACATGAA
CAGCCTGATTCTGCACAACAACCCGTTCCTGATCAGCCACGGCATTAAAAACAGCAACTTTACCTACAAC
GACCTGCTGGATAACGAAATCAGCTGGGTTAAGTGCCTGAACCTGAACACCTTCCAGACCCTGCTGATTC
CGGAGCAATATGCGTACTATGGTATTAACATCAGCAACCACAAGGAAAAAGCGATTAACATCGCGTACGA
GATCAGCAACGGTTGCAGCGTGGGCAACAACTATCTGGAAGTGGTTTACTATGGCCTGATGGAAGTTATC
GAGCGTGACAGCTTCCTGTGCAGCTGGTACTTTAACACCCCGAAGGATAAAATTAGCCTGAAAAACGCGA
GCACCAGCATCAAGAACCTGATTCAGCAATTCACCAGCTACTATAACGACTATAAACTGGAACTGTTCTA
CCTGTATAACGAGTTTAACATCCCGGTGGTTCTGGCGACCGTGACCCTGAAGGAAAGCAGCACCAAGAAA
ATGAACTTTATGTGCGCGGCGGCGGCGGACATTAACATCGAAGATGCGATCGAGAAAAGCATTCACGAGA
TCGGTGGCATTCTGTTCGGTCTGAACAAGAAATTTATCGATCGTTACCACGAGCTGGAAGCGATTCGTAA
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AAACAACCTGGACGTGAAGACCATGGAAGATCACACCCTGGTTTATGGCCTGCCGGAGCACCGTACCTAC
ATCCAGCAAAAGATGAACTACGAAAACATCTACGACTATGATAAGGAGCTGACCCCGAAAATCTTCTACA
AAGAGGTGCAGAAGCTGATCAAGAAAATTAGCACCACCAAGGACATTCTGCTGGTTGATCAAACCCCGCT
GATCAGCAAGAAAATTGACCTGAAAGTGGGTAAAATTATCGTTCCGGGCCTGCTGCCGATGACCTTTGGC
AAATACAACATCCGTGTTAGCGAAAACCGTTACCACGAGCTGTGCCACTTCTATAGCAAGGACCTGATTA
TCGATCTGAACCCGCACCCGTTTCCGTAAgtcgac

TclN (SalI/SacI) insert
gtcgacGGAGGTCACATATGGATATCAGCAAATTCCTGTACAACCTGCACTATAACCCGGGCGAGGTGGT
TAGCGCGAGCTACACCATCGAGGACACCATTCAGCGTAACAGCGAAGGTTTTTACAAGGGCTATGGTATC
GATTTCCTGAAACTGCAACAAAAGAGCCCGATCGTGAAAGTTATTCTGAAGAGCTACGGCGACATCTTCT
TTAACCGTGTGGAAAACAAGAAAAAGCCGCTGATCTTCTGCCGTAAAATGACCCCGAGCGGTGGCGGTCT
GTATCCGATCAACATTTTTATCTGCACCAACTTCAAGAACCGTATCGCGCTGTTCCAATTTGATTTCAAA
CGTAACCTGCTGATCTTCATCAAGTACATCAACATCGAGATCAACAACGAATGCACCAAACTGTACCTGG
TTCCGTGCTATACCCGTAACTACTTCAAGTACAAGGAGTTCAGCTATCGTCTGTGCCCGCTGGACACCGG
CTACCTGATCAGCACCCTGCTGTATAACTTTAGCGTGGAGAACATCACCTTCAAGCTGAGCATTAAACTG
AACAAGAACAGCGACATCACCGATGTTCTGAACGAAATCGGTTGCGAGGAAATTCCGTACAGCATCATTG
AGCTGAACGAAAGCCTGAACCTGGACAACCTGAGCCTGGAGCACTACGATACCGAAAGCTATTTCTTTAA
CCCGAACAAAGTGCGTAACCTGCTGGAGATCGACACCCTGATTCACCAGGAATACCACAAGGATATCAAC
ATCAACTTCAATAACGAGAACAAGCTGTTCGAGAAGTTCGAAATCCAAAAACGTATTAGCCCGGGTGGTG
AGTTCATCCAGAACAGCAAAGTGGAGCAAGAAAGCATTAACAAGTTTATCAGCCTGATTATGCAGTACAA
AAACAAGAGCAACTTCCTGAGCGAATATATCCTGCTGAACCTGATTGACGTTCAAAACAAGCGTATCATT
AACCTGAGCGCGAGCGAGTTTCTGAGCTACAAAAACAACGTGAGCATCGAATTTATTGATAAGCAGCTGA
CCCGTCGTAACTTCAACCTGCTGGCGGTTCCGTACATCCTGTATGTGGGCGTTAACGAGGAAAAAATTAA
GGAGAACTACAGCAACAACTACTTCAAAATCAGCCGTATCATCGCGGGCTTCTGGAGCGGTGTGGTTAGC
ATTCTGAGCGCGCAGTGCGGTCTGAGCACCCACCCGATGATGAGCTACAACGCGCGTGAACTGGAGGAAT
ACATCTTCAAGAACCGTTATAGCATTCTGAACCAAATCGTTATTGGCGGTAACATCACCACCAACCGTAT
GGACTCCATGCTGATTCGTAGCGATCTGTAAAAGCTGCCCgagctc

His6-TclI (KpnI/XbaI) insert
ggtaccGGAGGTCACATATGCATCATCACCATCACCATGGCGGAAGCTACCTGCTGTTCAAGAAAGACAC
CTTTTATATCAAGACCCACAACGAGGGTATTCTGTTCAAAAACAACTTTACCAACCTGGAAGTGAAGACC
CATAAAAGCTACTATGTTTTCGAGAACCTGATCGAATACCTGAACGGCAGCTATACCGAGAACCAGATCA
TCGAAAACATCAAGAACAAGAAAGTGGCGCTGTTCTGCAAAAACATCATTAACGTTCTGAAGGAGAAAAA
CTTTATCTACGCGAGCGAAAACCGTCTGGATAACCTGAGCGAGCTGGAAATCAAGATTCTGTATCTGAAC
AGCAAGAACATCCAACTGAGCAAAGACGCGTTCCTGAACAACAACAAGATCGATATTAAAACCTACAACC
TGATGGAGAACGAGTTCGCGAACACCATGCTGAAGGAGTACTATTTTAGCCCGAGCGAAACCGCGAACAT
CAAGATTAGCCTGGGTAAATTTGAGAGCGACATCGGCTACTATATCATTCCGGATGGTGAATACCTGATT
GTGGGCAAAAGCAAGAAACAGCACACCCACACCGTTAGCCTGAGCACCTATGAGATCCCGCTGCACGCGT
GGCTGATCTGCCTGAACATTCTGCTGAGCGAACTGTTCCTGTACTGCACCAGCATTTATAGCGAGGACAA
GTTCGATGAAAACTACTACAAGTTCAACGTGCAAACCTTTGAGGGTGACTTCTTTAAGAAAGAAAACAAA
TAAtctaga

His6-TclJ (XbaI/SalI) insert
tctagaGGAGGTCACATATGCATCATCACCATCACCATGGCGGAAGCGAAATCTTCGAAAGCCCGGAGTT
TAACATCATTCGTTACCTGAGCAACAGCTATATTTTCAAGAGCACCAGCAAAGAACCGGACTTTCTGAAC
AGCATCAAAGAGCGTATTCTGCTGAATACCAACGATATCATTTACAAGAAAAACATCCCGGAACGTAACA
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TTAGCTTCCTGAGCCGTATCGAGAACAGCATTGGTAACTTTATCTGCAACCAGATTAGCGAATACGACTA
CATCATCTACATCTACAACCACAAGACCAACAAGATCAAGAAAGTGAACTACTTCATCAGCCCGCACTAC
TATAAGAAACTGCCGAACGACACCACCAACTGCTTCAACATCATTATCAACGAGCTGAAGAACAGCAAAA
GCCACAACTTTCGTAGCCGTAACATTGATAGCATCTACAACCAGCTGGACAAATATTTCCTGGATAAGAA
CCTGGGTATCTGCAACATGCTGCTGGACAACTACGATGGCCCGTTTCCGATTAGCGTTGCGATGCTGCCG
CTGGACAACGGTAAAGAGGAACCGGGTGTGGGCCGTACCCGTAAGATCCAACGTAGCCGTGCGGTTGCGC
TGCTGGAAGCGTACGAGCGTTATAGCGGTCTGGAACCGCGTGGCAAGAAAACCATCAACCACACCGAGGA
TCTGAAGAGCAAGAAAGTGAACATGAACAGCCTGATTCTGCACAACAACCCGTTCCTGATCAGCCACGGC
ATTAAAAACAGCAACTTTACCTACAACGACCTGCTGGATAACGAAATCAGCTGGGTTAAGTGCCTGAACC
TGAACACCTTCCAGACCCTGCTGATTCCGGAGCAATATGCGTACTATGGTATTAACATCAGCAACCACAA
GGAAAAAGCGATTAACATCGCGTACGAGATCAGCAACGGTTGCAGCGTGGGCAACAACTATCTGGAAGTG
GTTTACTATGGCCTGATGGAAGTTATCGAGCGTGACAGCTTCCTGTGCAGCTGGTACTTTAACACCCCGA
AGGATAAAATTAGCCTGAAAAACGCGAGCACCAGCATCAAGAACCTGATTCAGCAATTCACCAGCTACTA
TAACGACTATAAACTGGAACTGTTCTACCTGTATAACGAGTTTAACATCCCGGTGGTTCTGGCGACCGTG
ACCCTGAAGGAAAGCAGCACCAAGAAAATGAACTTTATGTGCGCGGCGGCGGCGGACATTAACATCGAAG
ATGCGATCGAGAAAAGCATTCACGAGATCGGTGGCATTCTGTTCGGTCTGAACAAGAAATTTATCGATCG
TTACCACGAGCTGGAAGCGATTCGTAAAAACAACCTGGACGTGAAGACCATGGAAGATCACACCCTGGTT
TATGGCCTGCCGGAGCACCGTACCTACATCCAGCAAAAGATGAACTACGAAAACATCTACGACTATGATA
AGGAGCTGACCCCGAAAATCTTCTACAAAGAGGTGCAGAAGCTGATCAAGAAAATTAGCACCACCAAGGA
CATTCTGCTGGTTGATCAAACCCCGCTGATCAGCAAGAAAATTGACCTGAAAGTGGGTAAAATTATCGTT
CCGGGCCTGCTGCCGATGACCTTTGGCAAATACAACATCCGTGTTAGCGAAAACCGTTACCACGAGCTGT
GCCACTTCTATAGCAAGGACCTGATTATCGATCTGAACCCGCACCCGTTTCCGTAAgtcgac

GST-TclE (XbaI/SacI) insert
tctagaAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGTCCCCTATACTAGGTTATTGGAAAA
TTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTA
TGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCT
TATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACA
ACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAG
ATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTA
CCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCC
ATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTT
CCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGC
AAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAAGGAG
GAGAAAACCTGTATTTTCAAGGCGGATCCGAGTTCCAGACCAACAACATCGAAGGTCTGGACGTGACCGA
TCTGGAGTTTATTAGCGAGGAAGTTACCGAAAAGGACGAGAAAGAAATCATGGGTGCTTCTTGCACCACC
TGCGTGTGCACCTGTAGCTGCTGCACCACCTAACTGCAGCCAgagctc

TclN-His6 (SalI/SacI) insert
gtcgacGGAGGTCACATATGGATATCAGCAAATTCCTGTACAACCTGCACTATAACCCGGGCGAGGTGGT
TAGCGCGAGCTACACCATCGAGGACACCATTCAGCGTAACAGCGAAGGTTTTTACAAGGGCTATGGTATC
GATTTCCTGAAACTGCAACAAAAGAGCCCGATCGTGAAAGTTATTCTGAAGAGCTACGGCGACATCTTCT
TTAACCGTGTGGAAAACAAGAAAAAGCCGCTGATCTTCTGCCGTAAAATGACCCCGAGCGGTGGCGGTCT
GTATCCGATCAACATTTTTATCTGCACCAACTTCAAGAACCGTATCGCGCTGTTCCAATTTGATTTCAAA
CGTAACCTGCTGATCTTCATCAAGTACATCAACATCGAGATCAACAACGAATGCACCAAACTGTACCTGG
TTCCGTGCTATACCCGTAACTACTTCAAGTACAAGGAGTTCAGCTATCGTCTGTGCCCGCTGGACACCGG
CTACCTGATCAGCACCCTGCTGTATAACTTTAGCGTGGAGAACATCACCTTCAAGCTGAGCATTAAACTG
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AACAAGAACAGCGACATCACCGATGTTCTGAACGAAATCGGTTGCGAGGAAATTCCGTACAGCATCATTG
AGCTGAACGAAAGCCTGAACCTGGACAACCTGAGCCTGGAGCACTACGATACCGAAAGCTATTTCTTTAA
CCCGAACAAAGTGCGTAACCTGCTGGAGATCGACACCCTGATTCACCAGGAATACCACAAGGATATCAAC
ATCAACTTCAATAACGAGAACAAGCTGTTCGAGAAGTTCGAAATCCAAAAACGTATTAGCCCGGGTGGTG
AGTTCATCCAGAACAGCAAAGTGGAGCAAGAAAGCATTAACAAGTTTATCAGCCTGATTATGCAGTACAA
AAACAAGAGCAACTTCCTGAGCGAATATATCCTGCTGAACCTGATTGACGTTCAAAACAAGCGTATCATT
AACCTGAGCGCGAGCGAGTTTCTGAGCTACAAAAACAACGTGAGCATCGAATTTATTGATAAGCAGCTGA
CCCGTCGTAACTTCAACCTGCTGGCGGTTCCGTACATCCTGTATGTGGGCGTTAACGAGGAAAAAATTAA
GGAGAACTACAGCAACAACTACTTCAAAATCAGCCGTATCATCGCGGGCTTCTGGAGCGGTGTGGTTAGC
ATTCTGAGCGCGCAGTGCGGTCTGAGCACCCACCCGATGATGAGCTACAACGCGCGTGAACTGGAGGAAT
ACATCTTCAAGAACCGTTATAGCATTCTGAACCAAATCGTTATTGGCGGTAACATCACCACCAACCGTAT
GGACTCCATGCTGATTCGTAGCGATCTGAGCGGCGGACATCATCACCATCACCATTAACTGCAGCCCgag
ctc

His6TclINTD (KpnI/XbaI) insert
ggtaccGGAGGTCACATATGCATCATCACCATCACCATGGCGGAAGCTACCTGCTGTTCAAGAAAGACAC
CTTTTATATCAAGACCCACAACGAGGGTATTCTGTTCAAAAACAACTTTACCAACCTGGAAGTGAAGACC
CATAAAAGCTACTATGTTTTCGAGAACCTGATCGAATACCTGAACGGCAGCTATACCGAGAACCAGATCA
TCGAAAACATCAAGAACAAGAAAGTGGCGCTGTTCTGCAAAAACATCATTAACGTTCTGAAGGAGAAAAA
CTTTATCTACGCGAGCGAAAACCGTCTGGATAACTAAtctaga

His6TclICTD (KpnI/XbaI) insert
ggtaccGGAGGTCACATATGCATCATCACCATCACCATGGCGGAAGCGAAAACCGTCTGGATAACCTGAG
CGAGCTGGAAATCAAGATTCTGTATCTGAACAGCAAGAACATCCAACTGAGCAAAGACGCGTTCCTGAAC
AACAACAAGATCGATATTAAAACCTACAACCTGATGGAGAACGAGTTCGCGAACACCATGCTGAAGGAGT
ACTATTTTAGCCCGAGCGAAACCGCGAACATCAAGATTAGCCTGGGTAAATTTGAGAGCGACATCGGCTA
CTATATCATTCCGGATGGTGAATACCTGATTGTGGGCAAAAGCAAGAAACAGCACACCCACACCGTTAGC
CTGAGCACCTATGAGATCCCGCTGCACGCGTGGCTGATCTGCCTGAACATTCTGCTGAGCGAACTGTTCC
TGTACTGCACCAGCATTTATAGCGAGGACAAGTTCGATGAAAACTACTACAAGTTCAACGTGCAAACCTT
TGAGGGTGACTTCTTTAAGAAAGAAAACAAATAAtctaga

TclJNTD1 (XbaI/SacI) insert
tctagaGGAGGTCACATATGGAAATCTTCGAAAGCCCGGAGTTTAACATCATTCGTTACCTGAGCAACAG
CTATATTTTCAAGAGCACCAGCAAAGAACCGGACTTTCTGAACAGCATCAAAGAGCGTATTCTGCTGAAT
ACCAACGATATCATTTACAAGAAAAACATCCCGGAACGTAACATTAGCTTCCTGAGCCGTATCGAGAACA
GCATTGGTAACTTTATCTGCAACCAGATTAGCGAATACGACTACATCATCTACATCTACAACCACAAGAC
CAACAAGATCAAGAAAGTGAACTACTTCATCAGCCCGCACTACTATAAGAAACTGCCGAACGACACCACC
AACTGCTTCAACTAAgagctc

TclJNTD2 (XbaI/SacI) insert
tctagaGGAGGTCACATATGGAAATCTTCGAAAGCCCGGAGTTTAACATCATTCGTTACCTGAGCAACAG
CTATATTTTCAAGAGCACCAGCAAAGAACCGGACTTTCTGAACAGCATCAAAGAGCGTATTCTGCTGAAT
ACCAACGATATCATTTACAAGAAAAACATCCCGGAACGTAACATTAGCTTCCTGAGCCGTATCGAGAACA
GCATTGGTAACTTTATCTGCAACCAGATTAGCGAATACGACTACATCATCTACATCTACAACCACAAGAC
CAACAAGATCAAGAAAGTGAACTACTTCATCAGCCCGCACTACTATAAGAAATAAgagctc
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GST-TclEleader (XbaI/SacI) insert
tctagaAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGTCCCCTATACTAGGTTATTGGAAAA
TTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTA
TGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCT
TATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACA
ACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAG
ATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTA
CCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCC
ATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTT
CCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGC
AAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAAGGAG
GAGAAAACCTGTATTTTCAAGGCGGATCCGAGTTCCAGACCAACAACATCGAAGGTCTGGACGTGACCGA
TCTGGAGTTTATTAGCGAGGAAGTTACCGAAAAGGACGAGAAAGAAATCATGGGTGCTTCTTgagctc

L501A2 vector sequence
Features:

LacI ORF
TAC promoter
Multiple cloning site
AmpR ORF
ColE1 ori
GST-TclE
gtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgta
tccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtATGAGTATTCAA
CATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGC
TGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAG
CGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTA
TGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGA
ATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAG
GAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGA
ATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACT
ATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTT
GCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGC
GTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACAC
GACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAG
CATTGGTAActgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaattta
aaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttcca
ctgagcgtcagaccccgtagaaaagatcaaaggatcttcTTGAGATCCTTTTTTTCTGCGCGTAATCTGC
TGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTT
TTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGG
CCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCT
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GCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGT
CGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCT
ACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGC
AGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCG
GGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAaa
cgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcg
ttatcccctgattctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaa
cgaccgagcgcagcgagtcagtgagcgaggaagcggaagtctagtccgacaccatcgaatggtgcaaaac
ctttcgcggtatggcatgatagcgcccggaagagagtcaattcagggtggtgaatGTGAAACCAGTAACG
TTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCC
ACGTTTCTGCGAAAACGCGGGAAAAAGTGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGT
GGCACAACAACTGGCGGGCAAACAGTCGTTGCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCACGCG
CCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGG
TAGAACGAAGCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCT
GATCATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCG
TTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTCCCATGAAGACGGTACGCGAC
TGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAAGTTCTGT
CTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGCGGAA
CGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGTTC
CCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCT
GCGCGTTGGTGCGGATATCTCAGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCG
TTAACCACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTC
AGGGCCAGGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCC
CAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGA
CTGGAAAGCGGGCAGTGAgcgcaacgcaattaatgtaagttagctcactcattaggcacaattctcatgt
ttgacagcttatcatcgactgcacggtgcaccaatgcttctggcgtcaggcagccatcggaagctgtggt
atggctgtgcaggtcgtaaatcactgcataattcgtgtcgctcaaggcgcactcccgttctggataatgt
tttttgcgccgacatcataacggttctggcaaatattctgaaatgagctgTTGACAATTAATCATCGGCT
CGTATAATGtgtggaattgtgagcggataacaatttcacacaggaaactctagAAAGGAGGTGGAGGTCA
TGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCT
TGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAA
TTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCA
TCATACGTTATATAGCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAAT
GCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACT
CTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAA
CATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATA
CATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCA
CAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTG
GTGGTGGCGACCATCCTCCAAAAGGAGGAGAAAACCTGTATTTTCAAGGCGGATCAGAATTCCAAACAAA
CAATATCGAAGGTTTAGATGTCACTGATTTAGAATTTATCAGTGAAGAAGTTACTGAAAAAGACGAGAAA
GAAATCATGGGTGCTTCTTGTACTACATGTGTTTGTACATGCAGTTGTTGTACAACTTAAggatccggct
gacgcgtacaggaaacacagaaaaaagcccgcacctgacagtgcgggctttttttttcgaccaaaggtaa
cgaggtaacaaccatgcgagtgttgaagtggcagaactgctgaacgcaggtctgggcggttctgataacg
agtaatcgttaatccgcaaataacgtaaaaacccgcttcggcgggtttttttatggggggagtttaggga
aagagccagatccctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatgcg
ccgctacagggcgcgtcag
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Supplementary Table 4. Plasmid Table
Plasmid name

Parent Plasmid

Name in figure

Insert

pJG1013

pJG743

His6-TclI

His6-TclI

pJG1066

pJG743

His6-TclJ

His6-TclJ

pJG1068

pJG743

TclN-His6

TclN-His6

pJG1070

pJG743

TclIJN

TclI, TclJ, TclN

pJG958

pJG743

His6-TclIJN

His6-TclI, TclJ, TclN

pJG964

pJG743

His6-tclIJ

His6-TclI, TclJ

pJG965

pJG743

His6-TclIN

His6-TclI, TclN

pJG968

pJG743

His6-tclIE(GST-E)

His6-TclI, GST-TclE

pJG1047

pJG743

N/A

His6-TclINTD

pJG1051

pJG743

N/A

His6-TclINTD, TclJ

pJG1053

pJG743

N/A

His6-TclINTD, TclN

pJG1052

pJG743

N/A

His6-TclINTD, GST-TclE

pJG1038

pJG743

N/A

His6-TclICTD,

pJG1040

pJG743

N/A

His6-TclICTD, TclJ

pJG1042

pJG743

N/A

His6-TclICTD, TclN

pJG1041

pJG743

N/A

His6-TclICTD, GST-TclE

pJG1062

pJG743

N/A

His6-TclI, TclJNTD1

pJG1061

pJG743

N/A

His6-TclI, TclJNTD2

pJG1065

pJG743

N/A

His6-TclI, GST-TclEleader

pJG985

pED022

GST-TclE

GST-TclE

L501A2

N/A

N/A

GST-TclE

79

Supplementary Table 5. Strain Table
Strain

Background

Plasmid(s)

D104

BL21

pJG743

D158

BL21

pJG1012

D148

BL21

pJG1066

D149

BL21

pJG1068

D143

BL21

pJG985

D142

BL21

pED022

D091

BL21

pED022, pJG743

D147

BL21

pJG985, pJG1070

D094

BL21

pJG985. pJG958

D101

BL21

pJG964

D102

BL21

pJG965

D103

BL21

pJG968

D136

BL21

pJG1047

D132

BL21

pJG1051

D133

BL21

pJG1052

D134

BL21

pJG1053

D135

BL21

pJG1039

D116

BL21

pJG1040

D118

BL21

pJG1041

D117

BL21

pJG1042

D074

Nico 21

pJG958

D075

Nico 21

pJG964

D076

Nico 21

pJG965

D154

BL21

pJG1061

D155
D153
PB524

BL21
BL21

pJG1062
pJG1063
L501A2

DH5α
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